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CHAPTER 1
INTRODUCTION
1.1 Overview
Nanomedicine has recently gained popularity as a medical application of
nanotechnology in order to aid in the development of medical treatment,
diagnosis, monitoring, and control of biological systems.(Moghimi et al., 2005)
Drug delivery using nanocarriers has many potential advantages as for example
more efficient formulation, reduced side effects, higher bioavailability, longer
circulation and improved pharmacokinetics and biodistribution(Mirza and Siddiqui,
2014). Nanocarriers can be devised from natural or synthetic, organic or
inorganic materials such as dendrimers, liposomes, gold nanoparticles, proteinbased carriers, and viral-derived nanoparticles(Mirza and Siddiqui, 2014;
Moghimi et al., 2005). Many important advances in nanotechnology have been
already translated into medical research; several are FDA approved and
commercially available for treatment of different types of diseases such as
cancer,(Miele et al., 2009; Muggia, 2001; Wagner et al., 2006) hepatitis,(Zeuzem
et al., 2000) fungal infections,(Bawa, 2008) pain and influenza(Faraji and Wipf,
2009). Despite the progress accomplished in a wide spectrum of diseases in the
area of nanomedicine, there are no clinical applications of nanocarriers to
prevent or treat pregnancy-related complications, which begs the question: can
we use nanomedicine for the treatment of fetal and/or maternal complications? In
this introductory chapter I review the human placental tissue and its contribution
to pregnancy related complications; as well as a detailed comparison to mouse
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placenta, an analogous in vivo model. I also review the use of nanocarriers as
drug delivery tools to the placenta, focusing on the platforms we used: liposomes
and dendrimers and how we aim to utilize them to enhance the delivery of
therapeutics to the placenta in order to treat pregnancy related complications that
are caused by placental malfunction.
Pregnancy-related complications are common, affecting more than 20%
(approximately 26 million) of all pregnancies.(Duley, 2009) Some of those
complications include preeclampsia (PE), intrauterine growth restriction (IUGR),
gestational

diabetes,

fetal

hypothyroidism,

bacterial

and

viral

infections(McDonagh et al., 2004; Racicot and Mor, 2017; Silasi et al., 2015).
Many of such complications result from compromised functions of the placenta,
some

of

which

can

lead

to

maternal

and/or

fetal

mortality

if

not

controlled(Thornburg and Marshall, 2015). Administration of medications in the
maternal circulation can treat some diseases of pregnancy. Maternal steroids, for
instance, are used to accelerate fetal lung maturation(Roberts et al., 2017).
Cardiac drugs can also be used similarly to treat fetal arrhythmias(Oudijk et al.,
2000). Levothyroxine can be invasively injected to the amniotic fluid, although
being invasive and a less desirable route, to treat fetal hypothyroidism(Gulraze et
al., 2013). On the other hand, no effective treatments exist to treat several other
complications of the pregnancy, including PE and IUGR.(Romo et al., 2009) In
the case of PE, for instance, labor is the best option to mitigate the
disease,(McCoy and Baldwin, 2009) however, that is not always a possibility.
Therefore, hypertension medications are currently used to lower high blood
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pressure associated with PE(Roberts and Gammill, 2005). Anticonvulsant
medications are used if PE is severe(Sibai, 2004; Zuspan, 1966). Life style
changes such as bed rest is also often required. To understand many of those
diseases and be able to devise a strategy to approach them, it is essential to
understand the anatomy and physiology of the placenta as well as the
pathogenesis of such diseases.
1.2 Understanding the Placenta
1.2.1 Functions:
Placenta is a specialized organ that is present only during pregnancy. At
term, the human placental weight is approximately 500 g, has a diameter of 15–
20 cm and thickness of 2–3 cm.(Griffiths and Campbell, 2014) It functions by
separating two completely distinct circulations: maternal and fetal. It serves
several functions that contribute to the synchronization between pregnant
mothers, the fetus and the placenta itself.(John and Hemberger, 2012) It is
responsible for gas exchange between the two circulations and providing
nutrients from the maternal circulation to the fetal one as well as eliminating the
waste from the fetal circulation.(Nelson, 2015) The placental tissue also serves
as a barrier protecting the fetus from maternal infections and diseases, as well as
certain potentially harmful molecules. It is also a major site for metabolism. It can
metabolize several drugs and biologics.(Donnelly and Campling, 2014)
Moreover, the placenta is also a major endocrine organ that secrets more than
100 peptide and steroid hormones to the fetal or maternal circulations in order to
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modulate

different

functions

such

as

fetal

growth,

metabolism

and

parturition.(Burton and Jauniaux, 2015; Gude et al., 2004)
1.2.2 Development and Anatomy:
Placentation starts after implantation of the blastocyst (a newly developed
fertilized egg), where trophoblast cells begin proliferating and migrating to the
decidua part of the endometrium.(Wooding and Flint, 1994) Part of the
proliferating

trophoblast

starts

fusing

together

to

form

multinucleated

syncytiotrophoblast (SynT), which grow invaginations in the endometrium(Carter,
2007). Such invaginations make up independent functional vascular units called
cotyledons. The villous trees located within the cotyledons separate maternal
circulation from fetal circulation. The villus is composed of four layers: the SynT

Figure 1.1 Schematic drawing of a full-term placenta with a close-up to the placental
villi showing the SynT layer. http://pimeonline.blogspot.com
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layer, cytotrophoblast cells, connective tissue of the villus and the endothelium of
the fetal blood vessels arranged from the maternal to the fetal side, respectively.
Such arrangement continues for the first 20 weeks of gestational period.
However, after that, the cytotrophoblast layer disappears leaving the placental
barrier with the remaining three layers, placing maternal and fetal circulations
about 2 to 4 um in proximity as illustrated in Figure 1.1. This arrangement makes
the SynT layer to become the main barrier at the maternal-fetal interface.
The SynT layer is a multinucleated epithelial layer that is in direct contact
with the maternal blood and is covered on the apical (maternal) side with
branched microvilli that maximize the surface area for gas and nutrient/waste
exchange. The blood vessels that ramify through the villous stroma carry
embryonic/fetal blood, which serves as portal to fetal tissues(Robbins et al.,
2010). All these arrangements are the fetal part of the placenta, which is known
as the chorionic plate. The maternal part, on the other hand, is called the basal
plate. The basal plate contains the endometrium and it provides the endometrial
blood vessels that would pour into the space between the chorionic plate and the
basal plate; this space is known as the intervillous space. The maternal side is
arranged as basal plate, the decidua basalis and the endometrium from fetal to
maternal side, respectively. Figure 1.1 provides an illustration of the
arrangements of different parts of the human placenta.
1.2.3 Human VS Rodent Placenta:
The placenta in both humans and rodents serves the main purpose of
providing the interface between the mother and the fetus. It is through this
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interface all the functions mentioned above are accomplished. While there are
many differences between the two species, there are many similarities in terms
of placental development, anatomy and functions as illustrated in Figure 1.2
(Krishnan et al., 2013). From the maternal to the fetal side, the arrangement is as
follows: First region is the decidual basalis, which is the maternal portion of the
placenta that is in direct contact with the myometrium. Second region is the
junctional zone (jz, also know as basal zone) in mice and basal plate (bp, also
known as cytotrophoblastic shell) in humans.

bp

jz _____

_______

Figure 1.2 Illustration of similarities between human and mouse placentas
showing the analogous regions between the two species.(Krishnan et al., 2013)
Third region is known as the fetal placenta in humans and labyrinth in
mice. This region is the fetal part of the placenta and it develops from the zygote.
It is within the chorionic plate and is the region at which the villous trees
(chorionic villi) bathe in maternal blood within the intervillous space, as shown in
1.3 (Kulvietis et al., 2011). Within the core of the chorionic villi are the fetal blood
vessels that make up the umbilical arteries and veins.
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The human fetal placenta is functionally analogous the mouse labyrinth
despite slight structural differences (Georgiades et al., 2002). In mice, the
labyrinth consists of 3 layers of cells, and is therefore known as trichorial
placenta. On the other hand, fetal placenta has one layer and is known as
monochorial placenta. The three layers of the labyrinth are arranged as Layer I,
(cytotrophoblast) Layer II, and III SynT from maternal to fetal side,
respectively(Georgiades et al., 2002). It is important to emphasize that both
Layers I and II are in contact with the maternal blood. In the human fetal placenta,
which is analogous to mice labyrinth, only one SynT is present.

Figure 1.3 Comparative representation of human (third trimester) and rodent
(GD18.5) placentas showing their differences. Left, human placenta showing a
single layer (SynT) separating maternal and fetal circulations. Right, rodent
placenta showing three layers (2 SynT layers and one giant trophoblast)
separating the two circulations
1.2.4 Surface Receptors in the SynT Layer and Aminoglycosides as a
Targeting Moiety to SynT
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The SynT layer, as explained above, determines the possibility of uptake
of materials present in the maternal circulation and potentially transport to the
fetal circulation. Some molecules can pass freely via simple diffusion such as
gasses. Other molecules can pass via facilitated diffusion such as glucose.
Several other biomolecules including amino acids can only be taken up through
active transport (Jansson, 2001). Many other substances including riboflavin,
folic acid, cobalt and immunoglobulin G (IgG) are taken up via receptor-mediated
endocytosis. Hence, many receptors are expressed on the maternal side of the
SynT layer including megalin receptors,(Akour et al., 2015a; Akour et al., 2013;
Akour et al., 2015b) transferrin receptors,(Bergamaschi et al., 1990) porcine
growth hormone (pGH) and human growth hormone (GH) receptors (Velegrakis
et al., 2017).
Megalin receptors are also expressed on the apical surface of renal
proximal tubular epithelial cells and mainly responsible for the reabsorption of
proteins and vitamins (Akour et al., 2015b; Verroust et al., 2002; Verroust and
Christensen, 2002) via clathrin-dependent RME.(Verroust et al., 2002; Verroust
and Christensen, 2002) They are also expressed on the maternal side of the
placenta and responsible for uptake of vitamins, lipids, and hormones. Megalin is
thus a valuable target for ligand-modified nanocarriers to actively deliver drugs
and biologics to the placenta for the treatment of diseases of the pregnancy.
Such receptors have been shown to be expressed on the SynT layer of the
placenta of human and mice, as well as on human choriocarcinoma (BeWo) cells,
an in vitro placental cell model (Akour et al., 2015b; Lybbert et al., 2016; Saito et
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al., 1994; Storm et al., 2016).
Recent studies have shown Megalin to be receptors for gentamicin (GM),
an

antimicrobial

aminoglycoside

(AG)

that

is

produced

naturally

by

bacteria,(Weinstein et al., 1963) and such megalin-based endocytic processes to
follow Michaelis-Menten kinetics (Akour et al., 2015b). AGs are also known to
have low protein binding (Mehrotra et al., 2004). AG may thus serve as potential
targeting agents that modify the surface of drug containing nanocarriers so as to
improve targeting of the maternal-fetal interface.
1.3 Nanocarriers for Placental Drug Delivery:
Various platforms can be used as nanocarriers in drug containing
nanomedicines including liposomes, dendrimers, polymeric micelles, gold
nanoparticles, linear polymers (synthetic or natural), protein-based carriers, viralderived nanoparticles and many others (Mirza and Siddiqui, 2014; Moghimi et al.,
2005). In this dissertation, two different nanocarrier platforms (liposomes and
dendrimers) were used and therefore turn our focus on those nanocarriers, which
have different strengths as they relate to drug delivery and targeting to the
placenta and their translational potential.
Liposomes are the most widely used nanocarriers in drug containing
nanomedicine in the clinic and under clinical trials, and thus have well known
toxicity profiles, which is paramount for applications involving pregnant mothers.
Biodegradable dendrimers on the other hand provide an opportunity for improved
release profiles and thus PK and biodistribution of conjugated drug products, and
also provide for an opportunity to deliver high payloads and tailoring of surface
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properties to control their interaction with different physiological environments
including the blood and the cytosol.
1.3.1 Liposomes: are spherical lipid bilayer vesicles that can be used as
vehicles to carry hydrophilic and lipophilic small molecular weight drugs and
biologics within their hydrophilic core or hydrophobic lipid bilayer (Bozzuto and
Molinari, 2015a). The physicochemical properties of liposomes can be
manipulated so as to optimize their function. Size, for instance, can vary
depending on the method of preparation and can range from 20 nm to >1000 nm
(Akbarzadeh et al., 2013a; Bozzuto and Molinari, 2015a; Pattni et al., 2015)
Surface charge can also be modulated and is usually determined by the type
lipids used (Miller et al., 1998b) The length and saturation of the lipid tails affect
the transition temperature of the lipid itself leading to different release profiles
and stability (Wolfram et al., 2014). Thus, the type of lipid is usually selected
prudently. Many different molecules can be added to the surface of the lipids
that eventually form liposomes, including masking agents such as polyethylene
glycol (PEG) (decrease serum protein binding), (Papahadjopoulos et al., 1991)
imaging agents such as fluorescent dyes including cyanine and FITC (Gao et al.,
2018; Portnoy et al., 2011), and/or targeting moieties such as peptides, (Huang
et al., 2008; Yang et al., 2014) carbohydrates (Zhang et al., 2010), antibodies
(Heath et al., 1980; Heath et al., 1983) or other functional groups (Sercombe et
al., 2015). Moreover, several different drugs and biologics, can be encapsulated
within the liposomes including peptides, nucleic acids and small molecular weight
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drugs (Tiwari et al., 2012) as schematically illustrated in Figure 1.4 (Robson et
al., 2018).

Figure 1.4 Illustration of a liposome (lipid bilayer vesicle) with versatile
properties such as size, surface charge, surface modifications and capacity to
carry small molecular weight hydrophilic and lipophilic drugs and biologics.

1.3.2 Dendrimer Nanocarriers (DNCs): are hyper-branched synthetic
polymers made structured in a tree-like shape as illustrated in Figure 1.5. Each
added layer of branches is considered a generation starting with the core,
generation 1 (G1), G2, G3, G4 and so on. As the generation grows, so does the
molecular weight and size.

Because of the synthetic approach used to

synthesize such systems, they are the most monodisperse polymers available in
our toolbox (Biswas et al., 2012; Cheng and Xu, 2008; Nanjwade et al., 2009).
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They have unique properties including small nanoscale size (a few nanometers)
(Kolhe et al., 2006), high monodispersity, and a large number of functional
groups that can be used to conjugate the drug payload through liable bonds, or
other ligands so as to modulate their interaction with the physiological
environment (Duncan and Izzo, 2005; Yellepeddi et al., 2011), as well as other
probes that allow us to track such systems in vitro and in vivo (Wijagkanalan et
al., 2011; Zhu et al., 2010). Dendrimers can be prepared from a large variety of
chemistries including polyamidoamine (PAMAM), polypropyleneimine (PPI), polyL- lysine (PLL), poly(glycerol-co-succinic acid), melamine, poly(glycerol), 2,2bis(hydroxymethyl)propionic acid (Bis-MPA), poly(ethylene glycol) (PEG), and
others (Kesharwani and Iyer, 2015). Biodegradable polyester dendrimers are
very promising given they reduced toxicity profiles (Heyder et al., 2017; Kolhe et
al., 2006; Wijagkanalan et al., 2011) as the polyester bonds that connect the
branches lead to the slow disintegration of the polymer into fragments that can
be easily eliminated from the physiological environment (in a predictable
way)(Heyder et al., 2017) after delivery the payload to the intended tissue.

Figure 1.5. Illustration of a fourth generation (G4) dendrimer
containing 48 surface groups that can be used for conjugating
different molecules such as the drug cargo, targeting moieties,
tracer molecules, and other surface groups.
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1.3.3 Nanocarriers for Placental Drug Delivery (literature Review)
There have been several in vivo pre-clinical and ex vivo studies that
discuss the use of nanocarries for the placental drug delivery (Bajoria et al.,
1997a; Bajoria et al., 2013; Menjoge et al., 2011; Soininen et al., 2015; Valero et
al., 2018; Valero et al., 2017; Yu et al., 2017). The effect of certain physical
properties of (non-targeting) liposome including size (Bajoria and Contractor,
1997), surface charge,(Bajoria et al., 2013; Miller et al., 1998a) and physical
properties of the lipids (Grazia Calvagno et al., 2007) on the transport across the
maternal-fetal interface has been investigated. It was observed that small (70nm)
unilamellar liposomes showed enhanced uptake of a fluorescent dye in perfused
human term placenta compared to larger liposomes (>300nm), as measured
fluorometrically (Bajoria and Contractor, 1997). In terms of the surface charge of
liposomes, it was determined that anionic liposomes have increased placental
uptake of a encapsulated carboxyfluorescein in vitro (trophoblast cells) that was
quantified fluorometrically (Bajoria et al., 1997b). Another study by the same
group was done in perfused human term placenta in order to deliver thyroxine
(T4) to the fetus by encapsulating it in anionic small unilamellar liposomes where
results showed enhanced delivery compared to free T4, which was metabolized
to reverse triiodothyronine (rT3) (Bajoria et al., 1997a). This placental uptake on
anionic small unilamellar liposomes were also demonstrated in in vivo models
(Tuzel-Kox et al., 1995). On the other hand, cationic liposomes have been shown
to reduce drug uptake. A study showed that encapsulating warfarin, a drug that
passes the placenta freely, in cationic liposomes significantly reduced its
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passage to the fetus in perfused human term placenta (Bajoria et al., 2013).
Moreover, indomethacin (IND), a prostaglandin production inhibitor that reduces
uterine contractions and can pass the placenta freely causing fetal toxicity, was
encapsulated in cationic multilamellar liposomes in order to reduce transplacental
crossing. Results showed that cationic liposomes reduced the passage to the
fetus 7.6 folds compared to free IND (Refuerzo et al., 2015). All these studies
demonstrate that manipulating liposomal properties can serve different purposes
leading to variable end results.
Dendrimers have also been investigated for transplacental transfer
abilities. One study investigated the placental uptake of PAMAM dendrimers in
comparison with antipyrine, a freely diffusible molecule, and showed that the
former exhibited a significantly lower transfer from maternal to the fetal side
across the perfused human placenta, demonstrating the possibility of delivering
drugs to the mother but not the fetus (Menjoge et al., 2011). Another group used
PAMAM dendrimers to stabilize and deliver siRNA to the placenta of
preeclamptic rat model in order to reduce the secretion of sFlt1, an
antiangiogenic factor that is excessively secreted from the placenta, causing
preeclamptic symptoms. Results showed that employing PAMAM dendrimer
significantly reduced the secretion of the sFlt1 and led to improved pregnancy
outcomes in the preeclamptic rats (Yu et al., 2017).
More recently, modification of nanocarriers with moieties capable of
targeting the placenta has been in a timed pregnant mouse model. Liposomes
encapsulated with carboxyfluorescein or insulin-like growth factor 2 were
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incubated with tumor-homing peptides after liposome preparation were
administered to timed-pregnant mice on GD 11.5, 13.5, 15.5, and 17.5 and
compared to plain liposomes. Targeting liposomes significantly increased
placental weight and improved fetal weight (King et al., 2016b); however, with
studies involving nanocarriers, more specifically liposomes, it is imperative to
show the release profiles of the encapsulated materials to eliminate bias that can
be introduced via different release profiles between the targeting and control
liposomes. Moreover, the study shows quantification only based on fluorescence
localization of the carboxyfluorescein within the placental tissue. Furthermore,
targeted liposomes to the uterus have been employed to reduce preterm birth in
an in vivo (mouse) model of pregnancy. Indomethacin, a tocolytic agent that can
reduce uterine contractions but can cross the placenta and cause fetal
complications, was encapsulated in liposomes that were decorated with oxytocin
receptor antagonist to reduce placental passage and target the uterus. Results
showed inhibition of uterus contractility in ex vivo model and increasing drug
concentration in the uterus in vivo (pregnant mice), maintaining the preterm birth
rate (Refuerzo et al., 2016). Another study also designed liposomes with
conjugated antibodies that bind the extracellular domain of the oxytocin and
encapsulated with contraction-blocking or contraction-enhancing agents and
tested them in an in vitro model as well as timed-pregnant mice. In vitro results
showed the blocking and enhancing activities while in vivo results showed
significant accumulation of the targeted liposomes within the uterus of the
pregnant mice (Paul et al., 2017).
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More recent applications of targeted nanocarriers using lipid-PLGA
nanoparticles incubated with targeting peptides have also shown positive results
in terms of placental targeting (Zhang et al., 2018). Such nanoparticles were
modified with synthetic placental CSA-binding peptide (plCSA-BP) that can bind
to chondroitin sulfate A (CSA), a sulfated polysaccharide expressed on the
trophoblast layer. In vivo results show significant accumulation within the
placental tissue. The study also reported that (plCSA-BP) caused dramatic
placental and fetal developmental impairment. While targeted drug delivery to the
placenta can be beneficial, it is essential to consider the fate of the nanocarrier
and the safety of the fetus as well as the mother. This is illustrated in several
other studies that use nanocarriers that can impose toxicity to the fetus as well as
some maternal tissues.
1.4 Hypothesis and Objectives
We hypothesize that GM conjugation to lipid and dendrimer nanocarriers
will promote their uptake in the SynT layer of in vitro and in vivo placental models.
The rationale for this work is that GM is a substrate for megalin, a surface
receptor in the SynT involved in clathrin-medicated processes, and thus its
presence (and presentation) on the surface of the nanocarriers will lead to
specific interactions with the SynT layer, and thus accumulation of the cargo
encapsulated/conjugated by the nanocarriers. We propose to test our hypothesis
by preforming the work prosed in the following two aims:
Aim #01: Synthesize GM-modified lipid conjugates and investigate the
uptake of corresponding liposomal formulations in an in vitro (BeWo polarized
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monolayer) and in vivo (timed pregnant Balb/c) model of the SynT layer. We
hypothesize that the conjugation of GM on the PEG modified lipids (instead of
directly to the lipids) that will form the liposomes will be available to interact with
the megalin receptors, and that an increase in the density of the targeting moiety
on the liposomal surface will further promote its internalization.

We further

hypothesize that the presence of the low binding GM on the surface of
PEGylated liposomes will lead to stable nanocarriers in vivo, and thus promote
the targeting of the megalin receptors on the apical side of the SynT layer.
In Chapter 2, we report the details of this objective. Briefly, we report the
chemical synthesis of the lipid to the targeting moiety, gentamicin. We also report
the characterization using Matrix-Assisted Laser Desorption and Ionization
(MALDI) and Nuclear Magnetic Resonance (1H NMR) and the purification using
extraction and dialysis. We describe the preparation and characterization of
liposomes. Next is a detailed description of the in vitro and in vivo studies with
explanation of the biodistribution analysis both quantitatively (tissue extract and
semi-quantitatively (IVIS in vivo imaging system).
Aim #02: Synthesize GM-modified PEGylated polyester dendrimers and
investigate the uptake of corresponding dendrimer formulations in an in vitro
(BeWo polarized monolayer) and in vivo (timed pregnant Balb/c) model of the
SynT layer. For the in vivo study, we first investigate the pharmacokinetics (PK)
of the PEGylated GM-dendrimers in order to determine the time point at which
the biodistribution study is performed. Following that, the biodistribution is
executed at the determined time point. Concentrations in maternal tissues
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(placentas, kidneys, and liver) as well as fetuses are analyzed using both In Vivo
Imaging System (IVIS) and tissue extract are reported.
In Chapter 3, we explain the details of this objective. Briefly, we discuss
the chemical modification of the dendrimers, starting with partial conversion of
the dendrimer terminal –OH groups to –NH2, followed by the conjugation of
Cyanine 5.5 (Cy5.5) and finally the conjugation of HO-PEG-OCH3 (control) or
PEG-GM (targeting modification- in progress). Throughout this process,
purification and characterization using MALDI and 1H NMR are reported for every
step. Thereafter, we report the PK study with time points (0.25, 0.5, 1, 8, 24 and
48 h). Plasma concentration vs. time curves are plotted and evaluated for AUC,
t1/2, and Kel. Finally, biodistribution will be evaluated based on tissue extract and
IVIS imaging (similar protocols to those in Chapter 2).
Different from liposomes, dendrimers have the disadvantage of not having
a well-known toxicity profile in humans. However, they allow for the conjugation
of the therapeutic cargo through designer bonds that allow for more detailed
controlled of spatial and temporal release of the cargo and are thus also
proposed here.
1.5 Relevance and Innovation
This work is innovative in several aspects. We are the first group to
propose the use of AGs (in this case GM) as a targeting moiety to the placenta.
In particular, this is the first time that GM- modified lipids are synthesized and the
ability to target models of the placenta in vitro and in vivo demonstrated. Such
novel methods of targeting the placenta for the delivery of drug and biologics are

19

significant as they provide for a nanotherapy platform for the potential treatment
of diseases of the pregnancy.
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ABSTRACT
Every year, complications during pregnancy affect more than 26 million
women. Some of those diseases are associated with significant morbidity and
mortality, as is the case of preeclampsia, the main cause of maternal deaths globally.
The ability to improve the delivery of drugs to the placenta upon administration to the
mother may offer new opportunities in the treatment of diseases of the pregnancy.
The objective of this study was to develop megalin-targeting liposome nanocarriers
for placental drug delivery. Megalin is a transmembrane protein involved in clathrinmediated endocytic processes, and is expressed in the syncytiotrophoblast (SynT),
an epithelial layer at maternal-fetal interface. Targeting megalin thus offers an
opportunity for the liposomes to hitchhike into the SynT, thus enriching the
concentration of any associated therapeutic cargo in the placental tissue. PEGylated
(2 KDa) lipids were further modified with gentamicin (GM), a substrate to megalin
receptors, and used to prepare placental-targeting liposomes. The rate and extent of
uptake of a fluorescent probe encapsulated within the liposomes into an in vitro
model of the SynT (polarized BeWo monolayers) was assessed by flow cytometry.
Targeting liposomes containing 5 mol% GM-modified lipids enhanced the uptake of
the probe by 1.5 fold compared to the non-targeting control. An increase in mol% of
the modified lipid resulted in further enhancement in uptake 2 fold compared to the
control. In a competition assay, inhibition of the megalin receptors resulted in a
significant reduction in uptake of the fluorescence probe encapsulated in GMmodified liposomes compared to the uptake without free inhibitor (p < 0.0001),
indicating the involvement in the receptor in the internalization of the liposomes. The
ability of the targeting liposomes to enhance accumulation of a fluorescence probe
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was also assessed in an in vivo placental model - timed-pregnant Balb/c mice at
gestational day 18.5. The targeting liposomes increased the accumulation of a
conjugated fluorescence probe in the placenta with a total accumulation of 2.8% of
the initial dose, which corresponds to an increase of 94 fold compared to the free
probe (p<0.0001), and 2-4 fold compared to the non-targeting control liposomes
(<0.0001), as measured by both tissue extraction and ex vivo imaging. Taken
together, these results demonstrate that megalin-targeted liposomes may offer an
opportunity to enhance the delivery of therapeutics to the placenta for the treatment
of diseases of the pregnancy.

2.1 INTRODUCTION
More than 130 million newborns are delivered every year all over the
world.(Keelan et al., 2015a) Over 20% of those pregnancies experience at least
one complication (Duley, 2009). Some pregnancy-related complications lead to
high maternal and fetal morbidity and mortality, including cases of preeclampsia
(Roberts and Gammill, 2005), intrauterine growth restriction (IUGR),(Romo et al.,
2009) and bacterial (McDonagh et al., 2004) and viral(Racicot and Mor, 2017;
Silasi et al., 2015) infections. Preeclampsia affects about 8% of all pregnancies
and accounts for 10-15% of all maternal deaths globally(Duley, 2009). IUGR,
affects approximately 7-15% of all pregnancies(Yamashita et al., 2011) and is
commonly associated with premature delivery (Garite et al., 2004; Goldenberg et
al.,

2008).

Many

pregnancy-related

complications

originate

due

to

a

compromised placenta, which is, therefore, a valuable target for the delivery of
small molecule drugs and biologics (Al-Enazy et al., 2017; Audus, 1999).

23

The placenta is the tissue that governs the exchange of nutrients and
waste between the mother and the fetus (Griffiths and Campbell, 2014)

It

contains independent functional vascular units called cotyledons. The villous
trees located within the cotyledons separate maternal circulation from fetal
circulation. The syncytiotrophoblast (SynT) is a multinucleated epithelial layer in
the villous trees that is in direct contact with the maternal blood and is covered on
the apical (maternal) side with branched microvilli that maximizes the surface
area for gas and nutrient/waste exchange. The maternal side of the SynT layer
has been shown to express megalin receptors (Akour et al., 2015a; Akour et al.,
2013), which are involved in clathrin-mediated endocytic processes (Orlando et
al., 1998; Saito et al., 1994). Megalin is thus a potential target for ligand-modified
drug nanocarriers for the active targeting and delivery of therapeutic molecules to
the placenta.
Our team has previously shown that the uptake of gentamicin (GM) by
polarized human choriocarcinoma (BeWo) cells, an vitro model of the SynT (Li et
al., 2013; Poulsen et al., 2009), is mediated by megalin receptors.(Akour et al.,
2015b) These natural aminoglycosides (Clarot et al., 2004) have low plasma
protein binding affinity(Mehrotra et al., 2004) and have been extensively used in
the clinic to treat infections in both the expecting mother and fetus (Dashe and
Gilstrap III, 1997), and thus have known cytotoxic profiles. Such characteristics
make GM stand out as candidate targeting ligands to megalin.
Liposomes have been extensively employed in the clinic as nanocarriers
in drug products containing nanomedicines (Pattni et al., 2015) for the treatment
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of various diseases including malaria, influenza and different types of
cancers.(Bozzuto and Molinari, 2015b) Targeted delivery with liposomes can be
active or passive. While passive delivery depends on the unique physiology of
the targeted tissue (Šentjurc et al., 1999), active delivery involves surface
modification with a ligand, which can be a small molecule or a biomacromolecule
(Forssen and Willis, 1998; Tagalakis et al., 2011). Several ligands have been
conjugated to liposomes for active delivery such as folic acid, transferrin and
mannose.(Pattni et al., 2015)

Such surface-modified liposomes have been

shown to enhance tissue specificity of the nanomedicine (Derycke et al., 2004;
Gabizon et al., 2004; Lee and Low, 1995; Pattni et al., 2015; Song et al., 2008;
Zong et al., 2014) and consequently the therapeutic index of the encapsulated
cargo.
Liposomes have also been studied pre-clinically in in vivo models of
pregnancy to evaluate their potential for the delivery of drugs to the placenta
(Bajoria et al., 1997b) and are of particular importance for diseases of the
pregnancy given their known toxicity profiles (Parnham and Wetzig, 1993).
Physicochemical properties of liposomes have been exploited in order to
manipulate placental uptake. Small unilamellar liposomes were shown to
increase placental uptake (Tuzel-Kox et al., 1995) while multilamellar liposomes
decreased placental uptake (Refuerzo et al., 2015). Anionic liposomes also
exhibited increased placental uptake compared to a cationic counterpart (TuzelKox et al., 1995). Recently, a tumor-homing peptide was shown to accumulate in
the placenta of a mouse model of pregnancy (King et al., 2016a)
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Carboxyfluorescein encapsulated in PEGylated liposomes accumulated in the
placenta of pregnant mice and at a higher extent (as qualitatively assessed by
confocal microscopy) when the liposomes were pre-incubated with the tumorhoming peptides (King et al., 2016a).
Given the challenges and opportunities described above, the objective of
this work was to develop a megalin-targeting liposome that may serve as a
platform for active delivery of therapeutics to the placenta. We synthesized GMmodified lipids and prepared and characterized targeting liposomes with such
lipids. We assessed their interaction with both in vitro and in vivo models of the
placenta.

Targeting liposomes were shown to enhance the uptake of an

encapsulated fluorescence probe in polarized BeWo cells (in vitro model of the
placenta) in a megalin dependent way. These liposomes were also seen to
accumulate in the placental tissue in an in vivo pregnancy model (timed pregnant
Balb/c mice) at significantly greater concentrations than controls.
2.2 MATERIALS AND METHODS
2.2.1 Materials. Hydrogenated Soy Phosphatidylcholine (HSPC) and N(Carbonyl-methoxypolyethyleneglycol

2000)-1,2-distearoyl-sn-glycero-3-

phosphoethanolamine, sodium salt (DSPE-PEG2K) were purchased from NOF
America (White Plains, NY). 1,2-distearoyl-sn-glycero-3-phosphoethanolamineN-[amino(polyethylene glycol)-2000] (DSPE-PEG2K-NH2) was purchased from
Laysan Bio Inc. (Arab, AL). Gentamicin (GM), cholesterol (CHOL), chloroform
and ethanol were purchased from VWR Analytical. Fluorescein isothiocyanate
(FITC) was purchased from Thermo Fisher Scientific. Cyanine 5.5 was
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purchased from Lumiprobe (Hunt Valley, MD). Eagle's Minimum Essential
Medium (EMEM) and Trypsin-EDTA (1X) were purchased from Corning.
DMEM/F12 was purchased from Thermo Fisher and fetal bovine serum (FBS,
USDA Origin) was purchased from Serum Source International (Charlotte, NC).
Tissue culture flasks, non-essential amino acids (NEAA, 100X), Transwell inserts
(polyester membrane, 0.33 cm2, 1 m pore size) were purchased from VWR
International. Phosphate buffer saline (PBS, 1X, pH=7.4), Hank's Balanced Salt
Solution (HBSS, 1X, pH=7.4), citrate buffer (pH=4.5) and tissue digesting buffer
were

prepared

in

our

laboratories.

Di-tert-butyl

dicarbonate

(BOC),

(dimethylamino) pyridine,4- [4-(dimethylamino)pyridine, 99%] (DMAP), cesium
fluoride (CsF) (N,N-dimethylformamide), anhydrous, 99.8+% (DMF) and
hydrogen chloride, 4M in 1,4-dioxane, 99% were purchased from Alfa Aesar.
Succinic

anhydride

(SA),

[N-Hydroxysuccinimide

dimethylaminopropyl)-N`-ethylcarbodiimide

(NHS)

hydrochloride)

and

(N-(3-

(EDC)

were

purchased from Sigma Aldrich.
2.2.2 Synthesis and Characterization of Targeting Lipids.
The synthesis of the targeting lipid DSPE-PEG2K-GM was performed by
conjugating GM to the DSPE-PEG2K-NH2 as shown in Scheme 1. First, the
amine groups of GM were protected by addition of di-tert-butyl dicarbonate
(BOC) – Scheme 1a. Briefly, GM (0.0795 mmol) and sodium carbonate (0.7726
mmol) were dissolved in DI H2O. BOC (0.5023 mmol) was dissolved in 1 mL
acetonitrile and added drop-wise and the reaction was stirred for 24 h. The
reaction mixture was diluted with 10 mL DI H2O and then extracted with ethyl
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acetate (3 × 10 mL). The organic layers were combined and then dried over
anhydrous sodium sulfate for 30 min. The sodium sulfate was filtered off and the
organic solvent was removed by rotary evaporation and further dried under high
vacuum for 6 h to obtain BOC-protected GM product (GM-BOC). The GM-BOC
(0.075 mmol) was then dissolved in a 6 mL anhydrous ethyl acetate and reacted
with

succinic

anhydride

(SA,

0.15

mmol)

in

the

presence

of

4-

dimethylaminopyridine (DMAP, 0.15 mmol) and cesium fluoride (CsF, 0.03 mmol)
for 24 h to yield BOC-protected gentamicin terminated with a carboxyl group (COOH), GM-BOC-SA. The reaction mixture was diluted with 5 mL ethyl acetate
and purified by extraction against DI H2O (3 × 7 mL) and dried as explained
above. The product (0.037 mmol) was then dissolved in 10 mL anhydrous DMF
and reacted with EDC and NHS to activate the -COOH followed by the addition
of DSPE-PEG2K-NH2 (0.026 mmol) for 24 h to form DSPE-PEG2K-GM-BOC –
Scheme 1b. After the completion of the reaction, the DMF was removed by
vacuum for 6 h. The deprotection of BOC from the DSPE-PEG-GM-BOC product
was performed by dissolving it in 5 mL 4.0 M HCl in dioxane for 30 min followed
by removal of the solvent by a flow of nitrogen to yield the gentamicin-terminated,
PEGylated lipid DSPE-PEG2K-GM. Lastly, the final product was purified by
dissolving DSPE-PEG2K-GM in DMSO, adding it to a dialysis tube (MWCO 1000
Da) and dialyzing against DMSO for 24 h followed by dialysis against deionized
water for 24 h, with periodical exchange of the solvents. The final product was
lyophilized and obtained as powder. The DSPE-PEG2K-GM was characterized
by matrix-assisted laser desorption/ionization Time-of-Flight spectroscopy
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(MALDI-TOF, Voyager-DE PRO, JBI SCIENTIFIC) and proton nuclear magnetic
resonance spectroscopy (1H NMR, Bruker avance iii 400 mHz).
2.2.3 In vitro Studies
2.2.3.1 Liposome preparation.
Liposomes were prepared following the thin-film hydration method
(Akbarzadeh et al., 2013b; Laouini et al., 2012), and using sonication to produce
small unilamellar liposomes (ULV). Different molar ratios of HSPC, CHOL, and
DSPE-PEG2K or DSPE-PEG2K-GM were dissolved in chloroform in a round
bottom flask. The mixture was then vortexed to ensure homogeneity. Chloroform
was removed by rotary evaporation at 40 oC followed by high vacuum overnight
to ensure the removal of the residual organic solvent. The lipid film was then
hydrated with 3 mL of PBS to form liposomes. The liposome suspension was
sonicated for 10 min over ice with 30% power intensity using the OmniRuptor
250 Ultrasonic Homogenizer to obtain the optimal size, followed by centrifugation
at 141,000 rcfmax (Beckman Coulter XL-100K Optima Ultracentrifuge, SW41
Rotor) for 2 h at 4 oC to pelletize them.
2.2.3.2 FITC loading in Liposomes.
The liposome pellet was then reconstituted with 3 mL of citrate buffer (pH=
5.5) containing 0.1 mg/mL of FITC and incubated overnight at 4 oC to actively
load FITC within the liposomes following a previously established method (Fritze
et al., 2006). After overnight incubation, the liposomes were centrifuged again for
2 h at 4

o

C. The supernatant was collected and FITC concentration was

assessed, providing an indirect measure of the encapsulation efficiency (Indirect
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EE). EE was also assessed directly (Direct EE) by reconstituting the liposomes
in PBS, adding a fraction of that sample to ethanol (rupturing liposomes) and
subsequently quantifying the amount of FITC (Ohnishi et al., 2013; Panwar et al.,
2010).

Direct EE =

Indirect EE =

2.2.3.3 Liposome Characterization.
Three different formulations were investigated in the in vitro studies: GMtargeting liposomes containing HSPC:CHOL:DSPE-PEG2K-GM with molar ratios
of (5.5:4:0.5) named 5PEG2K-5GM and (5.5:3.5:1) named 10PEG2K-10GM.
The third group acting as the control lacking the GM-targeting moiety contained
HSPC:CHOL:DSPE-PEG2K with molar ratio of (5.5:3.5:0.5) and was named
5PEG2K-0GM. The hydrodynamic diamter (HD) and zeta potential (ζ), a
measure of the surface charge of the liposomes, were characterized by light
scattering (LS) using a Malvern Zetasizer Nano-ZS (Malvern, UK).
2.2.3.4 In vitro FITC Release. After determining the Direct EE, FITC release
from liposomes was evaluated under sink conditions. Briefly, a 3 mL aliquot of
liposomes containing encapsulated FITC was sealed in a dialysis tube with 8,000
MWCO. The tube was then dialyzed against a 40 mL PBS (10 mM, pH 7.4) at 37
o

C in the dark. The FITC released from the liposomes into surrounding PBS was
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analyzed by taking 0.1 mL samples from the dialysate at intervals 0, 15 min 30
min, and every hour from 1-6 h, and measuring the fluorescence of FITC
(Excitation: 490 nm, Emission: 525 nm) using Microplate Reader (BioTek
Instruments, Inc. Winooski, VA, USA). The samples were taken in triplicate and
returned to the dialysate buffer after the measurements were completed. The
amount of FITC was calculated based on an established standard curve.
Release profiles were obtained from three independent liposome formulations
with consistent EE.
2.2.3.5 Preparation and characterization of the in vitro Placental Model
2.2.3.5.1 Cell Culture.
Human Choriocarcinoma (BeWo) cells (which express megalin) were
cultured with DMEM/F12 medium supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin−streptomycin and incubated at 37 oC with 5% CO2.
Human hepatocellular carcinoma (HepG2) cells (used as a negative control as
they do not express megalin) were cultured with EMEM supplemented with 10%
(FBS) and 1% penicillin−streptomycin and incubated at 37 oC with 5% CO2
2.2.3.5.2 BeWo Monolayer Formation and Polarization.
The polarization of the BeWo cells was assessed indirectly by measuring
the transepithelial electrical resistance (TEER) as a function of time. Briefly,
BeWo cells were seeded into 24-transwell plate inserts with a pore size of 1 m
at a 150,000-cells/cm2 density. Medium was changed in both apical and
basolateral side every other day. TEER values were then recorded everyday for
9 days post-seeding using EvomX meter (World Precision Instruments Inc) and
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reported as a function of time. Background resistance was determined in blank
inserts.
2.2.3.5.3 Tight Junctions in the BeWo Monolayer.
The monolayer formation and polarization of the BeWo cells was also
verified using immunocytochemistry (ICC) by assessing the formation of tight
junctions between the cells. BeWo cells were seeded into 24-transwell plate
inserts with a pore size of 1 m at a 150,000-cells/cm2 density and allowed to
grow for 6 days post-seeding. Cell monolayers were fixed on Transwell insert
membranes using 4% paraformaldehyde for 20 minutes. After fixation,
nonspecific binding was blocked by 2% BSA in PBS. Monolayer membrane was
then incubated with primary rabbit ZO-1/TJP1 antibody (Invitrogen) for one hour
at room temperature followed by one hour incubation with donkey anti-rabbit
antibodies (Life Technologies). Nuclei staining was accomplished by incubation
with Hoechst 33342 (Thermo fisher Scientific) for 20 minutes. Monolayers were
washed 3 times for 5 minutes after each of the previous steps. Lastly, the
membrane was cut, mounted on a slide and visualized using confocal laser
scanning microscope (Zeiss LSM 700)
2.2.3.5.4 BeWo Monolayer Cross-Section.
Cross-sections of the cell monolayers grown on inserts were processed at
the VCU Microscopy Core Facility. Briefly, BeWo cells were grown on the inserts
at the same conditions as mentioned above. On the sixth day post-seeding the
BeWo cell monolayer was fixed with 2.5% glutaraldehyde in 0.1 M phosphate
buffer (pH 7.4) overnight. Samples were then dehydrated using a serious of
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ethanol concentrations followed by Toluidine Blue/Azure II/ methylene blue
staining. Finally, samples were cut into 1-µm slices using an ultramicrotome and
visualized using the light microscope.
2.2.3.5.5 Liposomal Targeting in vitro.
Internalization of FITC encapsulated in liposomes was determined by flow
cytometry using Cytoflex Flow Cytometer (Beckman Coulter) following a method
previously described by our laboratories.(Bielski et al., 2015; Zhong et al., 2016a)
Briefly, BeWo cells were grown into confluent, polarized monolayers in a 96transwell plate by seeding 150,000-cells/cm2 and allowed to grow for 6 days as
described earlier. On day 6, each well was washed twice and incubated in sterile
Hank’s Balanced Salt Solution HBSS buffer for 30 minutes followed by the
addition of the non-targeting and targeting liposomal formulations (5PEG2k-0GM,
5PEG2k-5GM, 10PEG2k-10GM) each containing 250 ng of encapsulated FITC.
At time points 0.25, 0.5, 1, 2, 3, 4, 5, 6 h, after contacting with the liposomes, the
cell monolayers were washed thrice with cold sterile HBSS (1X, pH 7.4),
incubated with trypsin-EDTA, and resuspended in 0.5 mL HBSS. Samples were
run in the flow cytometer where the median fluorescence intensity (MFI) of FITC
was recorded to analyze the rate and extent of cellular internalization of the FTIC
encapsulated in the liposome systems as a function of GM density and time.
Similar experiments were performed in HepG2 cell monolayers, which serve as a
control cell line that does not express megalin receptors. Finally, Competition
studies were performed in BeWo monolayers using similar procedure as
described above, and comparing FITC internalization in the presence and
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absence of (2 mM) free GM, which was incubated with the cell monolayers 20
minutes prior to the liposomal treatments. The GM concentration of 2 mM was
chosen based on cell viability assay – BeWo cells are 100% viable at that
concentration, as shown in Figure S2.3.
2.2.4 In Vivo Experiments.
2.2.4.1 Synthesis of Cy5.5-modified PEGylated Lipids: DSPE-PEG2K-CY.
Cyanine5.5 (Cy5.5-COOH) was conjugated to DSPE-PEG2K-NH2 for the
preparation of liposomes used for the in vivo studies - Scheme S1. Briefly, the
Cy5.5-COOH was activated by reacting with NHS and EDC (both 1.5 molar eq.)
in dry DMSO. The activated Cy5.5 was then reacted with DSPE-PEG2K-NH2 at
0.8 molar eq., followed by addition of the products to a dialysis tube (MWCO
1000 Da) and dialyzing against DMSO for 24 h followed by dialysis against
deionized water for 24 h. The final product, DSPE-PEG2K-CY, was lyophilized
and obtained as powder and characterized by (MALDI-TOF) - Figure S2.1.
2.2.4.2 Preparation of Targeting Liposomes for in vivo studies.
For the in vivo studies, lipoid-conjugated Cy5.5 (DSPE-PEG2K-CY) was
used as a tracer instead of encapsulated FITC, thus allowing us to overcome
issues associated with tissue auto-fluorescence that prevents accurate
biodistribution assays with FITC. The same liposomal preparation method
mentioned earlier was used in this case, except for the FITC encapsulation steps.
Briefly, HSPC, CHOL, DSPE-PEG2K or DSPE-PEG2K-GM and DSPE-PEG2KCY were mixed in chloroform in the following molar ratio: 5.33:4:0.5:0.17,
respectively. Chloroform was removed and the lipid film was hydrated and

34

sonicated. The HD and ζ of the liposomes were determined as described earlier.
Non-targeting (control) 10PEG2K-0GM-CY and targeting liposomes 10PEG2K10GM-CY, both with 10mol% PEGylated lipids were investigated in vivo.
2.2.4.3 Timed pregnancy.
All animal experiments were performed in accordance with the guidelines
of the Institutional Animal Care and Use Committee at Virginia Commonwealth
University (IACUC approved protocol # AD10001841). Eight-week-old female
Balb/c mice (20-22 g) were housed under a 12 h light/dark cycle and allowed
food and water ad libitum. After mating, female mice were inspected daily to
observe the presence of a mating plug. Upon detection of the mating plug,
gestational day 0.5 (GD 0.5) was assigned. Due to Balb/c strain having higher
chance of false positive mating plugs, we further assessed pregnancy by tracking
weights of the pregnant females, as discussed previously(Heyne et al., 2015).
Biodistribution / targeting experiments were carried out at GD18.5, at which
placental barrier is analogous to human third trimester placenta(Georgiades et al.,
2002). Female mice were divided in 4 treatment groups as follows: Group 1:
PBS; Group 2: free Cy5.5; Group 3: non-targeting liposomes (10PEG2K-0GMCY); and Group 4: targeting liposomes (10PEG2K-10GM-CY). On GD 18.5, mice
were administered the formulations retro-orbitally with 0.70 mg/Kg Cy5.5
equivalent. Four hours post treatment, mice were euthanized, followed by
laparotomy; fetuses and maternal tissues (placentas and kidneys) were collected
for analysis. We chose 4 h exposure time based on previous liposomal
studies.(Refuerzo et al., 2015; Refuerzo et al., 2016; Tuzel-Kox et al., 1995)
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2.2.4.4 Biodistribution: ex vivo imaging and tissue quantification.
The ability of the liposomes to target the placenta was indirectly assessed
by measuring the concentration of Cy5.5 in tissue. Ex vivo Cy5.5 fluorescence
intensity of each tissue was measured using IVIS Imaging. After tissue excision,
they were washed in PBS (pH. 7.4) and placed in the IVIS chamber for
measurement at 680/710 nm. For each mouse, the average intensity of five
placentas, five fetuses, and two kidneys were assessed, and this was repeated
for n=4 pregnant mice. For the tissue extraction studies, the total dose of Cy5.5
was also directly determined in relevant tissues, for a total of n = 4 pregnant mice
for each group.

In this case, calibration curves were constructed by spiking

known amounts of Cy5.5 in placenta (3 placentas pooled together) and fetus (1
fetus), and Cy5.5 assessed per gram tissue. Similar placental pooling was done
when assessing biodistribution. Each tissue (or pooled tissue) was washed in
PBS (pH.7.4), placed in known volume of digesting buffer (0.5 M phosphate
buffer) and mechanically broken down using tissue homogenizer to create a
uniform suspension. Tissue suspension was allowed to shake/rotate for 72h at
4°C. Subsequently, each tissue homogenate was centrifuged for 10 min at 14000
g at 4°C. Supernatant was collected and fluorescence intensity was measured
(excitation/emission 680/710 nm) using microplate reader (BioTek Synergy HT).
Cy5.5 concentration was measured based on established calibration and
expressed as % of initial dose (% ID) per gram tissue. Absolute concentrations
are reported in Supporting Information. This procedure follows previously
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established methods in our laboratories for tissue quantification of fluorescent
probes (Zhong et al., 2016b).
2.2.5 Statistical Analysis.
All data are presented as mean ± standard deviation (SD). Each
measurement had a minimum of four independent repeats (n ≥ 4) in which the
mean and SD were subsequently calculated. GraphPad Prism 7 software was
utilized to perform two-way analysis of variance (ANOVA) followed by Tukey’s
Multiple Comparison Test. Means were considered statistically significant if p <
0.05. P-values were categorized as *p < 0.05, **p < 0.01, ***p < 0.001 and ****p
< 0.0005.
2.3 RESULTS AND DISCUSSION
2.3.1 Ligand Design and Synthesis of the Targeting Lipid.
2.3.1.1 Ligand Design.
There are several reasons for selecting gentamicin (GM) as the ligand to
develop placental-targeting liposomes. First, GM is a substrate of megalin, which
is a surface receptor in the apical (maternal) side of the SynT layer (Akour et al.,
2013). This is relevant as megalin is known to be involved in clathrin-mediated
endocytosis processes in the human placenta (Orlando et al., 1998; Saito et al.,
1994), and is also expressed in the in vivo (mouse) and in vitro (polarized BeWo
cell monolayers) models of pregnancy used in this work (Akour et al., 2015b;
Saito et al., 1994). GM also has unique physicochemical properties as a targeting
agent(Oroojalian et al., 2017) as it has low plasma protein binding affinity (Nagai
and Takano, 2004; Pechere and Dugal, 1979) and is expected, therefore, to
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confer enhanced stability to liposomes when in systemic circulation, thus further
promoting their placental targeting ability. Moreover, GM is currently used in the
clinic to treat maternal and fetal infections during pregnancy (Ward and Theiler,
2008) and thus has a known toxicity profile.
2.3.1.2 Synthesis of the Targeting Lipids.
The DPSE-PEG2K-GM targeting lipids were conjugated as illustrated in
Scheme 1. GM is composed of three major components known as C1, C1a and
C2 (Gberindyer et al., 2017; Seidl and Nerad, 1988; Sun and Liu). These major
components have slightly different molecular weights: 472, 486, 500 Da,
respectively – see Scheme 1a. GM has 5 amine groups, which we believe are
involved in its uptake into the SynT by megalin. Therefore, we conjugated GM to
the lipid using a hydroxyl (-OH) group instead.
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Scheme 2.1: Schematic of the chemical synthesis of the targeting lipid DSPEPEG2K GM.
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Figure 2.1 (a) MALDI-ToF spectra showing the main three peaks of
gentamicin (GM, 478, 486, 500Da), BOC-protected gentamicin (GM-BOC,
972, 986, 1000Da) and the succinic anhydride (SA) modified protected
gentamicin (GM-BOC-SA, 1072, 1086,1100Da). (b) 1H NMR spectra
showing the successful modification of gentamicin (GM, black) with BOC
(GM-BOC, in red) and SA (GM.BOC-SA, green).
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The NH2 groups of GM were first protected with BOC (MW: 101 Da
leading to GM-BOC products of mass corresponding to 972, 986, 1000 Da,
respectively. After protection, a carboxyl functionality (-COOH) was added to
GM-BOC via conjugation of succinic acid to the more reactive–OH, to form GMBOC-SA, with expected masses of 1072, 1086, 1100 Da, respectively. MALDIToF spectra for the various GM conjugates are shown in Figure 2.1a.
These chemical modifications were followed, as well, using 1H NMR
(Figure 2.1b). When compared to the spectrum of the free drug, it is possible to
observe the appearance of new peaks due to the chemical modifications
discussed. Firstly, the introduction of BOC groups resulted in the appearance of
a strong peak in the range 1.37-1.40 ppm (-CH3). Additionally, the new peaks in
the region 6.33-6.92 ppm correspond to the hydrogens present in the -NH-Boc
group, confirming the protection of all amine groups. The reaction with succinic
anhydride lead to new peaks in the range of 2.43-2.47 ppm (very close to the
residual solvent peak), which correspond to the new -CH2 groups conjugated to
the molecule. Besides those, a broad peak is present at 12.18 ppm,
corresponding to the -COOH group. GM-BOC-SA was subsequently conjugated
to DSPE-PEG2K-NH2 forming an amide bond as shown in Scheme 1b. The
DSPE-PEG2K-GM-BOC (MW: ~3861 Da), was lastly deprotected (BOC groups
removed), yielding the targeting lipid DSPE-PEG2K-GM, with an m/z of ca.
3500Da. MALDI-ToF spectra are shown in Figure 2.2.
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Figure 2.2 MALDI-ToF results showing DSPE-PEG2K (2792Da, black),
conjugated DSPE-PEG2K to SA-modified, protected gentamicin (DSPEPEG2K-GM-BOC, 3961Da, red) and the deprotected final product, the targeting
lipid DSPE-PEG2K-GM (3500Da, blue).
2.3.2 In vitro studies.
2.3.2.1 FITC-loaded Liposome Preparation and Characterization.
Three different liposomes were prepared for the in vitro studies:
PEGylated liposome with 5 mol% PEGylated lipid (i) without GM modification
(without targeting ligands) (5PEG2K-0GM) and (ii) with targeting ligands
(5PEG2K-5GM), and PEGylated liposome with a higher mole fraction of
PEGylated lipids (10 mol%) that were modified with the targeting ligands
(5PEG2k-10GM).

The size (hydrodynamic diameter, HD in nm) and surface

charge (zeta potential, ζ in mV) of the various formulations are summarized in
Table 2.1.
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Table 2.1: Hydrodynamic Diameter (HD), Zeta Potential (ζ), FITC
Encapsulation Efficiency (EE) and percent release at 6h (pH 7.4) for the three
different liposomal formulations used in the in vitro studies. SD = standard
deviation, n = 4.
ζ (mV)

EE (%)

% Release at 6h
(pH 7.4)

105 ± 12

- 4.4 ± 2.3

86.5 ± 7.2%

28.7 ± 1.5%

5PEG2K-5GM

112 ± 18

- 4.3 ± 2.5

84.4 ± 3.3%

28.2 ± 1.6%

10PEG2K-10GM

117 ± 19

- 3.7 ± 3.3

85.2 ± 8.3%

27.0 ± 1.6%

Liposome

HD

5PEG2K-0GM

SD (nm)

5PEG2K-0GM = liposomes prepared with 5mol% of DSPE-PEG2K lipid.
5PEG2K-5GM = liposomes prepared with 5mol% of DSPE-PEG2K-GM lipid.
10PEG2K-10GM = liposomes prepared with 10mol% of DSPE-PEG2K-GM lipid.
Non-targeting liposome controls 5PEG2K-0GM showed an average HD of
105

12 nm, with the targeting liposomes 5PEG2K-5GM and 5PEG2k-10GM

having a similar (not statistically different from the non-targeting control) HD of
112

18 and 117

19 nm, respectively. The size of liposomes is a critical

attribute(Juliano and Stamp, 1975) and impacts their behavior including cellular
uptake.(Bajoria and Contractor, 1997) The preparation of liposomes with similar
sizes thus helps remove confounding effects that may arise due to size
differences.
The zeta potential ( ζ ) of all liposomes is slightly negative and very close
(no statistically significant difference) among the three formulations with
5PEG2k-0GM -4.4
-3.7

2.3 mV, 5PEG2K-5GM -4.3

3.3 mV, as measured in PBS.

2.5 mV and 10PEG2K-10GM

These negative ζ happen in spite of the
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presence of GM that has 5 protonatable amines each.

This is important as

cationic liposomes have been shown to significantly reduce placental uptake of
liposomes when compared to anionic counterparts (Bajoria et al., 2013).
The encapsulation efficiency (EE %), drug loading and release profiles
were also consistent among the three systems. The encapsulation of FITC was
86.5

7.2%, 84.4

5PEG2K-0GM,

3.3% and 85.2

5PEG2K-5GM

and

8.3% of the starting FITC amount for
10PEG2K-10GM,

respectively,

as

summarized in Table 2.1. The loading efficiency of FITC was ca. 7 wt./wt.%
drug-to-lipid ratio. Although it was possible to achieve higher loading efficiencies,
this amount was sufficient to work with in terms of fluorometric analysis.
The release profiles are shown in Figure 2.3 and were seen to be
consistent among the different formulations throughout the first 6 hours with
28.7%, 28.2% and 27.0% being released at the end of 6h incubation at pH 7.4.
The fact that the three systems follow the same release profile helps remove any
confounding effect that may arise regarding rate and extent of uptake of FITC in
the monolayers due to liposomal (encapsulated FITC) vs. free FITC (released
FITC) in the medium as will be discussed next. Overall, the characteristics of the
three systems were not impacted by the presence of GM on the liposomes, or by
the different mol % of the targeting lipid containing PEG 2000Da. In fact, the
small ratios of GM used to prepare the liposomes may explain the consistency in
profiles for size, zeta potential, drug loading, encapsulation and release among
the three formulations.

Comulative Release (%)
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Figure 2.3 Cumulative amount of FITC released from actively-loaded, nontargeting (5PEG2K-0GM, red dotted line) and targeting (5PEG2K-5GM – blue
dashed line, and 10PEG2K-10GM green line), liposomes at pH 7.4 over 6 hours incubated at 37 0C. Data represents mean ± SD (n = 4). 5PEG2K-0GM =
liposomes with 5 mol% DSPE-PEG2K lipid; 5PEG2K-5GM = liposomes with 5
mol% DSPE-PEG2K-GM lipid; 10PEG2K-10GM = liposomes with 10 mol%
DSPE-PEG2K-GM lipid
2.3.2.2 The in vitro Placental Model.
BeWo cells have been shown to express megalin receptors, and when
polarized monolayers are formed, BeWo cells have been shown to be involved in
the uptake of gentamicin in a megalin-mediated manner (Akour et al., 2015b).
Establishing polarized monolayer was thus essential for this cell line in order to
be used as a model for the syncytiotrophoblast (SynT) layer. TEER was recorded
to assess the integrity of the monolayer. Figure 2.4a shows the increase in
TEER values over a period of nine days post cell seeding. TEER values plateau
at 40-50

2

around days 5-6.

Optimal micrographs of tin sections of
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prepared system (Figure 2.4b) show the formation of monolayers, compared to
multilayers formed on day 7 and beyond - Figure S2.2b. BeWo monolayer
polarization was confirmed by staining of the tight junction ZO1 proteins - Figure
2.4c. Monolayers were initially characterized on days 5, 6, 7 and 8. Day 6 was
chosen to carry out the FITC internalization studies based on the plateauing of
TEER values, formation of tight junctions and the presence of a monolayer (vs.
multilayer on later days).
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Figure 2.4: (a) Transepithelial electrical resistance (TEER) of BeWo monolayers
cultured on 0.33 cm2 Transwell® inserts as a function of time. Data represents
mean ± SD (n = 4). (b) 40X optical image showing a cross-section of the BeWo
monolayer on the 6th day post seeding (DPS). (c) ZO-1 staining of a confluent
BeWo monolayer obtained on the 6th DPS, indicating tight junction formation.

2.3.2.3 Targeting the in vitro placental model.
2.3.2.3.1

Uptake

in

BoWo

Monolayers.

The uptake of FITC encapsulated in the different liposomal formulations by
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BeWo polarized monolayers and a control monolayer (HepG2, which does not
express megalin) was evaluated as a function of time using flow cytometry.
Formulations containing two levels of GM at 5PEG2K-5GM and 10PEG2K-10GM,
and the negative control (5PEG2K-0GM) were studied.
As shown in Figure 2.5, the extent and rate of internalization of liposomes
were significantly enhanced upon the addition of the targeting agent - 5PEG2K5GM (p < 0.0001) and 10PEG2K-10GM (p < 0.0001) at 6 h, compared to the
control 5PEG2K-0GM. During the first time point (15 min), there was no
significant increase of uptake among compared to the control. At time = 0.5 h, the
formulation with 10mol% targeting lipid 10PEG2K-10GM showed a significant
increase (p = 0.0362) compared to control; however, the uptake profile for
5PEG2K-5GM remained not significantly different compared to control. Such
uptake profile is not uncommon for the early time points as previously shown for
liposomal systems with different targeting moieties (Hong et al., 2009; Zidan and
Aldawsari, 2015).
After 1 h, uptake of 5PEG2K-5GM and 10PEG2K-10GM liposomes was
significantly enhanced (p = 0.0357 and p < 0.0001 respectively) compared to the
control group. At time = 2 h and longer contact times, both systems sustained
significantly enhanced FITC uptake (p < 0.0001).

Increasing the mol% of

targeting lipid (compared 10PEG2K-10GM and 5PEG2K-5GM) also led to
enhancement in FITC uptake at all times, except 0.25h.
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Figure 2.5: Cellular internalization of FITC on polarized BeWo cells (6th day post
seeding) determined by flow cytometry, as a function of time post contacting the
monolayer with FITC-encapsulated liposomes. The median fluorescence
intensity (MFI) data represents mean ± SD (n = 4), with at least 6,000 events
(singlets). 5PEG2K-0GM = liposomes with 5 mol% DSPE-PEG2K lipid; 5PEG2K5GM = liposomes with 5 mol% DSPE-PEG2K-GM lipid; 10PEG2K-10GM =
liposomes with 10 mol% DSPE-PEG2K-GM lipid.

2.3.2.3.2 Uptake in Hepatocellular Carcinoma (HepG2) Monolayers.
Uptake of FITC encapsulated in 5PEG2k-0GM and 5PEG2K-5GM was
also studied in hepatocellular carcinoma (HepG2) monoalyers. HepG2 was used
as negative control, as it does not express megalin receptors (Akour et al.,
2015b). Figure 2.6 shows the cellular uptake of FITC at 0.25, 3 and 6 h. There is
no significant difference between the two systems at the three time points (p >
0.999, p = 0.872 and p = 0.4528 respectively). These results support the idea

47

that increases in uptake of FITC in BeWo cells seen for the liposomes with GMmodified lipids in Figure 2.5 are due to specific interactions between GM and the
megalin receptors, which we expect to lead to enhanced internalization of FITC
via fluid phase endocytosis.

(HepG2)

5PEG2K-0GM
5PEG2K-5GM
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Figure 2.6: Normalized cellular Internalization of FITC on HepG2 cell
monolayers determined by flow cytometry, as a function of time post contacting
the monolayer with FITC-encapsulated liposomes. The median fluorescence
intensity (MFI) data represents mean ± SD (n = 4) with at least 6,000 events
(singlets). 5PEG2K-0GM = liposomes with 5 mol% DSPE-PEG2K lipid; 5PEG2K5GM = liposomes with 5 mol% DSPE-PEG2K-GM lipid.

Increases in FITC uptake with time for the targeting liposome systems
(Figure 2.6) are expected even for monolayers that do not express megalin due
to the fact that liposomes are known to be internalized via different endocytic
mechanisms (Duzgune et al., 1999; Friend et al., 1996; Straubinger et al., 1983).
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This includes those that are not receptor mediated as e.g. macropinocytosis
(Swanson and King, 2018) and is also due to the internalization of free FITC that
is being released from the liposomes as a function of time.
2.3.2.3.3 Competitive Inhibition of Megalin Receptors.
Competitive inhibition studies were carried out by saturating the megalin
receptors with free GM before contacting the targeting and non-targeting
liposome formulations with the polarized BeWo monolayers.

Saturation was

accomplished by adding 2 mM free GM in HBSS media 15 to the cell monolayer
minutes prior to the addition of liposomal formulations. This molar concentration
was selected based on the fact that BeWo cells retain 100% viability under such
conditions – see Supporting Information - Figure S2.3. The uptake of 5PEG2K5GM was seen to be significantly higher than the control liposome (p<0.0001) in
the absence of free GM (GM -) as seen in Figure 2.7 (as also shown in Figure
2.5); however, in the presence of 2 mM free GM (GM +), the uptake of 5PEG2K5GM was significantly reduced and seen not to be statistically different compared
with non-targeting control 5PEG2k-0GM (p = 0.0599).
Put together, the cellular internalization experiments described in this work
support the idea that GM-modified liposomes are internalized in polarized BeWo
monolayers via megalin-mediated endocytosis, and that the ability to target
megalin leads to enhancement in the rate and extent of internalization of FITC,
the encapsulated probe.
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5PEG2K-0GM
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5PEG2K-5GM
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Figure 2.7 Normalized cellular Internalization of FITC on polarized BeWo cells
(6th day post seeding) in the absence and presence of free gentamicin (Free GM;
2mM) determined by flow cytometry at 6 h post contacting the monolayer with
FITC-encapsulated liposomes. The median fluorescence intensity (MFI) data
represents mean ± SD (n = 4) with at least 6,000 events (singlets). 5PEG2K0GM = liposomes with 5 mol% DSPE-PEG2K lipid; 5PEG2K-5GM = liposomes
with 5 mol% DSPE-PEG2K-GM lipid; 10PEG2K-10GM = liposomes with 10 mol%
DSPE-PEG2K-GM lipid.

These results are of importance as they represent a novel strategy to
potentially target the placenta and enhance the delivery of drugs and biologics to
treat a variety of diseases of pregnancy. The liposomes with 10mol% targeting
lipids (and the respective control) were thus selected to carry out the in vivo
studies.
2.3.3 In Vivo Studies.
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2.3.3.1 Synthesis and Characterization of Cy5.5-modified lipids (DSPEPEG2K-CY).
Synthesis of the Cy5.5-conjugated lipid was achieved in a one-step
reaction – Scheme S1. DSPE-PEG2K-NH2 (MW ca. 2790 Da) was reacted with
Cy.5.5-COOH (MW 619 Da) via an amidation reaction to yield DSPE-PEG2K-CY
(3400 Da), which was characterized by MALDI-ToF as shown in Figure S2.1.
2.3.3.2 Liposomal Formulations for in vivo Studies.
Liposomal formulations for in vivo studies were prepared with the Cy5.5
probe (DSPE-PEG2K-CY lipids) to avoid any potential sensitivity issues with
FITC due to tissue background auto-fluorescence. The liposomal formulations for
in vivo studies with the DSPE-PEG2K-CY lipid exhibited similar HD and ζ as the
formulations with encapsulated FITC, as shown in Table S1, demonstrating that
the presence of small amounts of the CY-lipid conjugate do not significantly
impact the characteristics of the liposomes. The non-targeting liposomes
(10PEG2K-0GM-CY)

and

the

targeting

(10PEG2K-10GM-CY)

liposomes

prepared with 1.7mol% of DSPE-PEG2K-CY and 10 mol% of PEGylated lipid
(without or with GM targeting) had HDs of 103 nm and 114 nm, and ζ of -5.4 and
-3.4 mV, respectively.
2.3.3.3 Targeting the in vivo placental model.
The in vivo biodistribution of Cy5.5 in pregnant mice was evaluated via an
in vivo imaging system (Xenogen IVIS Spectrum), and also by tissue extraction
and quantification of the fluorescence of Cy5.5. The total flux of Cy5.5 of the
excised placental, fetal, and maternal kidney tissues for the treatment groups
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including free Cy5.5, and the targeting and non-targeting liposomal formulations
are shown in Figure 2.8a. Images of those tissues are shown in Figure 2.8b,
including the PBS controls.
The results indicate that the total flux from the Cy5.5 probe in the placenta
is significantly enhanced (p=0.009) by formulation of Cy5.5 in the PEGylated
liposomes compared to free Cy5.5. It is likely that the prolonged circulation times
of PEGylated liposomes(Kooijmans et al., 2016) combined with a SynT layer that
has a high surface area and is highly irrigated by maternal blood(Georgiades et
al., 2002) promotes the contact of the probe with the placenta when in liposome
formulation, leading to its enhanced accumulation. Other studies have shown
that physicochemical properties of PEGylated liposomes were manipulated to
enhance delivery of placental limited-uptake drugs to the placenta(Bajoria and
Contractor, 1997; Bajoria et al., 1997a; Bajoria et al., 2013; Valero et al., 2018).
The presence of the targeting moiety in the 10PEG2K-10GM-CY liposome
formulations further promotes (p<0.0001) the accumulation of Cy5.5, leading to a
3.7 fold increase in flux in the placental tissue when compared to the nontargeting control liposomes. The results show that the presence of the targeting
ligand GM not only leads to the preparation of liposomes with similar
characteristics in terms of HD and ζ to the non-targeting PEGylated controls, but
also seems to indicate that it does not negatively impact the in vivo stability of the
formulation, as GM has low plasma protein binding(Pechere and Dugal, 1979).
For fetal tissues, IVIS imaging showed no significant accumulation of
either free Cy5.5 (p=0.3599) or Cy5.5 formulated in the liposomes (p 0.9917 and
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0.9149, for non-targeting and targeting, respectively) compared to the control
fetal tissue (PBS administration) (n=6) or amongst each other. On the other hand,
kidneys also show an increase in uptake of Cy5.5 formulated in liposome form
compared to free Cy5.5, similar to placental tissues. Targeting further increased
the uptake of Cy5.5 by 3.9 fold (p <0.0001) as expected as this tissue also
expressed megalin receptors.(Campeiro et al., 2019; Faber et al., 2006)
Considering an average of 5 placentas, the flux ratio (all placentae to both
kidneys) is ca. 2X, indicating a significantly higher placental accumulation for the
targeting liposomes.
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Figure 2.8: (a) Total flux of Cy5.5 for free Cy5.5, 10PEG2K-0GM-CY and
10PEG2K-10GM-CY liposomes measured ex vivo by IVIS imaging showing
placentas, fetuses and kidneys 4 hr post treatment. Results shown have been
subtracted from background which are fluxes of tissues exposed to PBS control
only; (b) representative images of the placental and fetal tissues, as well as
kidneys for the various treatment groups. 10PEG2K-0GM-CY = non-targeting
liposomes with 10 mol% DSPE-PEG2K lipid and 1.7 mol % DSPE-PEG2K-CY
lipid; 10PEG2K-10GM-CY = targeting liposomes with 10 mol% DSPE-PEG2KGM lipid and 1.7 mol % DSPE-PEG2K-CY lipid.

The distribution of Cy5.5 in placental and fetal tissue was also assessed
by tissue extraction (n=4). Figure 2.9 shows the fluorometric analysis based on
an established calibration curve, with the inset indicating the % accumulation in
the placenta relative the initial dose of 25ug of Cy5.5.
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Average concentration of Cy5.5 from 10PEG2K-10GM-CY targeting
liposomal formulations was ca. 88 fold greater than free Cy5.5. Mirroring the
IVIS results, the targeting liposomes led to ca. 2 fold increase the accumulation
of

Cy5.5

compared

to

the

non-targeting

10PEG2K-0GM-CY

liposomal

formulation, with the following accumulated amounts in the placenta: 10PEG2K10GM-CY: 1405

10 ng/g (2.81% total dose); 10PEG2K0GM-Cy, 685

(1.34% total dose); free Cy5.5, 128

3 ng/g (0.03% total dose); p<0.0001).
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Figure 2.9: (a) Quantitative analysis (ng/g tissue) of Cy5.5 for control (no
exposure to Cy5.5), free Cy5.5, 10PEG2K-0GM-Cy and 10PEG2K-10GM-Cy
liposomes measured from homogenized tissues 4 hr post treatment; (b) same
results plotted as % initial dose (%ID) – total of 25ug in tissue. Cy5.5 assessed
fluorometrically by microplate reader and concentrations obtained based on
established calibration curves on spiked tissues. 10PEG2K-10GM-CY = targeting
liposomes with 10 mol% DSPE-PEG2K-GM lipid and 1.7 mol % DSPE-PEG2KCY lipid.
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Fetal analysis shows no significant accumulation of Cy5.5 (no statistical
difference from PBS control) for any of the treatments groups (10PEG2K-10GMCY, 14 ng/g; 10PEG2K-0GM-CY 17 ng/g; free Cy5.5, 25 ng/g). While the current
placental-targeting liposomal formulations do not show significant increases in
the fetus in mice, it is important to reemphasize the anatomical differences
between placenta of humans and rodents. Having three layers (two SynT layers
and a third trophoblast layer)(Georgiades et al., 2002) at GD18.5, as opposed to
one SynT layer in human third trimester placenta (Georgiades et al., 2002), mice
placenta may represent a stricter barrier than that of humans, thus showing less
transplacental transport of certain compounds (Kulvietis et al., 2011).
2.4 CONCLUSION
In this study we synthesized gentamicin (GM)-modified PEGylated lipids
and demonstrated that the corresponding liposomal formulations prepared with
these lipids promote the uptake of associated fluorescent probes in both in vitro
(polarized BeWo monolayers) and in vivo (timed pregnant mice) placental
models. GM is a substrate of megalin (Akour et al., 2013), a transmembrane
protein in the apical side of the syncytiotrophoblast (SynT) layer of the maternalfetal interface (human and murine placentae and BeWo cells), and the
nanocarriers prepared here were designed to hitchhike those clathrin-mediated
processes that megalin is involved in. Targeting liposomes promoted the uptake
of the associated fluorescent probe in polarized BeWo monolayers to a
significantly greater extent than the non-targeting PEGylated analogs, and the
extent of uptake increased as the density of targeting lipids in the liposomes
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increased. We also observed that competition for megalin receptors resulted in a
decrease in uptake of the associated probe in targeting liposomes to the same
level of non-targeting liposomes, further supporting the role of megalin endocytic
processes in the uptake. In in vivo biodistribution experiments (IVIS and direct
quantification by tissue extraction), formulation of the probe as conjugate to lipids
resulted in significant enhancement in uptake in the placental tissue compared to
the free probe. This is likely due to improved circulation of the conjugated probe,
while no measureable amounts of the probe were found to transport into the fetal
tissue. Addition of targeting lipids to the liposomal formulation further enhanced
the uptake of the conjugated probe, leading to 2-4 fold higher uptake in the
placenta compared to the non-targeting liposomes, while the probe is still not
seen into fetal tissue. The proposed GM-targeting liposomal nanoformulations
may serve as a platform for the delivery of small molecule therapeutics and
biomacromolecules to support the treatment of diseases of pregnancy.
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3.1 INTRODUCTION
There have been significant recent advances in the use of drug containing
nanomedicines (Kesharwani and Iyer, 2015). There are several advantages in
using nanotechnology for drug delivery including the ability to control the
pharmacokinetics and biodistribution of the therapeutic cargo (Pattni et al., 2015),
reduction

of

side

effects

(Lim

et

al.,

2012),

enhancing

sustained

release(Natarajan et al., 2014), and providing new strategies for the delivery of
poorly soluble drugs (Gao et al., 2002). Several fields have benefited from
nanomedicine such as oncology, ophthalmology, cardiology and microbiology
(Doane and Burda, 2012; Shi et al., 2010). Moreover, numerous drug containing
nanomedicines have been approved by the FDA, including Doxil ®, a treatment
of many different types of cancer. More recently, nanotechnology approaches
have been proposed to tackle diseases of pregnancy (Refuerzo et al., 2016; Yu
et al., 2017), which are very prominent and contribute to many maternal and fetal
health problems with significant morbidity and mortality including preeclampsia
(Roberts and Gammill, 2005). Some in vitro and in vivo model studies have
shown promising results with regards to the delivery of therapeutics to the
placenta in order to improve the health of the growing fetus (Refuerzo et al.,
2016; Valero et al., 2018; Valero et al., 2017); however, there is a still a long way
to go in terms of developing drug containing nanomedicines for the treatment of
diseases of pregnancy. There are many considerations when designing
nanocarriers that can target the placenta to treat such disease including the
potential toxicity that can be imposed to the mother or the fetus. Thus, it is
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essential to consider the fate of such nanocarriers and whether there is a
collateral damage associated with their use. In this chapter we discuss the
potential of polyester dendrimers as a platform for the delivery of therapeutics to
the placenta. While our end objective is to develop gentamicin (GM)-modified
dendrimers for targeting megalin in the SynT, as we did for liposomes, here we
report initial studies of PEGylgated polyester dendrimers (their chemistry and
characterization) and the design and initial steps in the preparation of GMtargeting dendrimers. We discuss PK results in non-pregnant animals to make
preliminary determination of optimum times in which to study the biodistribution in
the placenta and fetus of such carriers, which are our future experiments. We
also have planed for the future in vitro uptake studies once the targeting
dendrimer has been synthesized and characterized.
3.2 MATERIALS AND METHODS
3.2.1. Materials.
Gentamicin (GM), chloroform and ethanol (EtOH) were purchased from
VWR Analytical. Cyanine 5.5 (Cy5.5) was purchased from Lumiprobe (Hunt
Valley, MD). Eagle's Minimum Essential Medium (EMEM) and Trypsin-EDTA
(1X) were purchased from Corning. DMEM/F12 was purchased from Thermo
Fisher and fetal Phosphate buffer saline (PBS, 1X, pH=7.4), Hank's Balanced
Salt Solution (HBSS, 1X, pH=7.4) were prepared in our laboratories. Di-tert-butyl
dicarbonate (BOC), 4-(Dimethylamino)pyridine (DMAP, 99%), cesium fluoride
(CsF), N,N-dimethylformamide anhydrous (DMF, 99.8+%) and hydrogen chloride,
4M in 1,4-dioxane (99%) were purchased from Alfa Aesar. Succinic anhydride
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(SA),

n-hydroxysuccinimide

(NHS)

and

N-(3-Dimethylaminopropyl)-N`-

ethylcarbodiimide hydrochloride (EDC) were purchased from Sigma Aldrich.
BOC-6-aminohexanoic acid was purchased from Alfa Aesar.
3.2.2.

Synthesis

and

Characterization

of

Gentamicin-PEG1000Da

conjugated, Cy5.5-modified, generation 4, polyester dendrimers (G4OHPEG1K-GM).
Previously we successfully synthesized 3 systems of non-PEGylated
generation 4 polyester dendrimer (G4OH) by conjugating FITC (G4OH-FITC) and
GM (G4OH-GM) directly on the surface of the dendrimer. MALDI-ToF and 1H
NMR characterization is shown in Figure S 3.1. Due to water solubility issues
and potential issues related to the proximity of the targeting agent to the
dendrimer surface, in the end we decided to change the route of the synthesis by
including PEG as solubility enhancer, and also as a flexible spacer to conjugate
the targeting GM to the dendrimer surface. In this new approach, we first
conjugated a near infrared dye Cy5.5, which is commonly used in the in vivo
studies and avoid tissue background issues as it happens with FITC.
In this new approach we used G4OH was obtained from previous
synthesis in our laboratories (Heyder et al., 2017). A fraction of terminal –OH
groups of the dendrimer were first modified to –NH2. Briefly, G4OH dendrimer
was reacted with BOC-6-aminohexanoic acid in the presence of DMAP and EDC
followed by deprotection in 4M HCl in dioxane to yield partially –NH2-terminated
dendrimer, where 15 groups out of 48 terminal groups were converted. The
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product was reacted with Cy5.5 in the presence of NHS and EDC to yield G4OHNH2-Cy5.5 (Intermediate product).
G4OH-NH2-Cy5.5 and HOOC-PEG1000 were reacted via an amidation
reaction to give the final non-targeting control G4OH-NH2-CY5.5-PEG (named
CY-G4OH-PEG1K. This product was purified by dialyzing against DMSO for 24
hrs followed and against water for 8 hrs with continuous replacement of the outer
medium. Final product was lyophilized and stored as powder.
For the targeting dendrimer, the intermediate product G4OH-NH2-Cy5.5
was reacted with bifunctional HOOC-PEG1000-NH2 with its amines protected
giving Cy5.5-G4OH-NH2-PEG-NH2-BOC followed by deprotection in 4M HCl in
dioxane. Cy5.5-G4OH-NH2-PEG-NH2 was then reacted with the previously
synthesized GM-BOC-SA, as described in Chapter 2. The final product (work in
progress) will be deprotected to give the final product, the PEGylated targeting
dendrimer CY-G4OH-PEG1K-GM.
Characterization of each step of the synthesis was performed using
MALDI-TOF and 1H-NMR. The hydrodynamic diameter (HD in nm) and surface
charge (zeta potential – ζ in mV) of the dendrimer were characterized by Light
Scattering using Malvern Zetasizer Nano-ZS (Malvern, UK).
3.2.3. In Vivo Experiments.
While our final goal is to measure the biodistribution of the targeting
dendrimer and the control in the placenta (and fetal tissue), among other
maternal tissues, because the targeting dendrimer was not finished yet, here we
report only the pharmacokinetic studies performed in non-pregnant mice. These
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PK results will help us understand the best time after administration of the
dendrimers at which to collect initial biodistribution results. It will also help us
determine the stability of the polyester dendrimer in the in vivo model.
3.2.3.1 Pharmacokinetic Study in non-pregnant mice
The formulations were administered through a retro-orbital injection of 10
µg Cy5.5 eq. dose /mouse (20-22 g). Blood was collected at 0.25h, 0.5h, 1h, 8h,
24h and 48h via retro-orbital blood collection method for one time point followed
by a terminal point for the following point. Blood was mixed with EDTA in
ependorf tubes to prevent clotting. Blood samples were centrifuged for 15
minutes at 5000 RPM and plasma was collected. Plasma concentration of Cy5.5
was determined fluorometrically using a microplate reader (SynergyH1, Biotek),
based on a pre-determined calibration curve in plasma. Plasma concentration vs.
time curves were plotted and AUC, t1/2, and Kel determined using GraphPad
Prism 7.
3.2.4 Statistical Analysis. All data is presented as a mean ± standard deviation.
Each measurement had a minimum of three independent trials (n ≥ 3) in which
the mean and standard deviation were subsequently calculated. When necessary,
GraphPad Prism 7 software was utilized to perform two-way analysis of variance
(ANOVA) followed by Tukey’s Multiple Comparison Test.

Means were

considered statistically significant if p < 0.05. P-values were categorized as *p <
0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0005
3.3 RESULTS AND DISCUSSION
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3.3.1 Dendrimer Modification: hydroxyl terminated, generation 4, polyester
dendrimers (G4OH) were synthesized in our laboratories as descried
earlier(Heyder et al., 2017).

G4OH was modified with –NH2 shown in the

Schematic 3.1.
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Scheme 3.1 Schematic overview of the partial conversion of –OH to NH2,
followed by conjugation of Cy5.5 then mPEG1K
MALDI-ToF (Voyager-DE/JBI SCIENTIFIC) and 1H-NMR results show –
Figure 3.1S and 3.2S in Supplemental Information. Results show that 15 out of
48 terminal groups were successfully modified to –NH2, as indicated by a shift in
the mass of the G4OH from 5353 Da to 7412 Da (Figure S3.2), with each -NH2
functional group representing a mass of 130 Da. 1H NMR results show that the
reaction with boc-protected amino hexanoic acid, and subsequently deprotection,
led to the appearance of new peaks related to the -CH2 groups from the amino
acid (1.31, 1.51, 1.57, 2.28, 2.74 ppm). Those peaks were used to assign the
number of conjugated linkers, which is calculated as 15 (Figure S 3.4 a, b).

2
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Cy5.5 (583 Da) was subsequently conjugated to the G4OH-NH2 dendrimers via
an amide bond. The successful addition of Cy5.5 was observed in the MALDIToF (Figure S3.3 – Supplemental Information) through the appearance of a peak
at 8698 Da. The conjugation of the dye was confirmed by 1H NMR by the
appearance of peaks in the 7.5-8.5 ppm range (related to the rings and double
bonds of the structure) and the number of conjugates was determined through
the integration of the peak at 6.35 ppm. This peak was selected due to the fact
that it is very isolated from other peaks and no overlap was observed. The
integration of it showed the conjugation of 1.8 molecules of dye per dendrimer
(Figure S3.4 c).
Following the conjugation of Cy5.5, the product was divided to two
batches for further reaction: control dendrimer (PEGylated and no GM), and
targeting dendrimer (PEGyalated with GM-modified PEG). For the control
dendrimers, HOOC-PEG-OCH3 (mPEG, 1160 Da) was conjugated via amidation
reaction. MALDI-ToF shows an increase of the mass to 18500 indicating the
addition of 8 PEG 1KDa (Figure S3.5). This was confirmed by 1H NMR by the
appearance of a very intense peak at 3.51 ppm, which is correspondent to the CH2 units of the polymeric chain. To quantify the number of polymer chains
connected, we used the integration of the terminal methyl group (-CH3) of mPEG
at 3.24 ppm. It was determined that 10.2 PEG chains were conjugated per
dendrimer (Figure S3.4 d). Additionally, in the spectrum of this final structure it is
possible to observe the peaks of Cy5.5 showcasing that the dye was not affected
by the reaction between dendrimer and mPEG.
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For the targeting dendrimer, after HOOC-PEG-NH2-BOC was conjugated
to the dendrimer, MALDI-ToF results show a shift in peaks from 8698 to 20000
Da (Figure S3.6). Deprotection and conjugation of GM is in progress.
A summary of the characteristics for the various dendrimer cognates
intermediates and the final targeting and control dendrimers is shown in Table
3.1.

The characteristics include number of –NH2 surface groups, number

PEG1K and PEG1K-GM, and number of Cy5.5, as measured by MALDI-ToF (M)
and 1H-NMR (N).

Table 3.1 Molecular weight, number of Cy5.5, mPEG, and GM-PEG as shown by
MALDI-ToF (M) and 1h NMR (N), the hydrodynamic diameter (HD) and surface
charge (zeta potential, ζ) of the G4 polyester dendrimer conjugates.
G4OH

MW (Da)

#CY 5.5
M N

mPEG
M N

PEG-GM
M N

HD (nm)

CY-G4OH-PEG1K

170900

2

1.8

8

10

0

7±3

-15.4

2

1.8

0

0

TBD

TBD

TBD

CY-G4OH-PEG1K-GM

0

3.3.2 Pharmacokinetics (PK)
The plot of plasma concentration of Cy 5.5 as a function of time is shown
in Figure 3.1.PK analysis for the PEGylated polyester dendrimer CY-G4OHPEG1K shows (t1/2) at 4.1 h, with elimination rate constant (Ke) of 0.169 h-1.

ζ

(mV)
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Mean residence time was 4.8 h while total systemic clearance (Cltot) was 0.0059
ml/min. Area under the curve (AUC) was 17066305.04 ng/ml*min.
Based on this analysis, we will perform the biodistribution study at that time point
4 h. At this time point, we will perform our biodistribution study as 50% of the
dendrimer has been distributed/eliminated. Similar studies will be performed for
the targeting dendrimer. Once those experiments have been performed, we will
measure biodistribution in pregnant animals.

Figure 3.1 Plasma concentration (Cp) analysis as a function of time after retroorbital administration of CY-G4OH-PEG1K. Concentrations are reported in log
values (ng/ml)
3.4 CONCLUSION
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Polyester dendrimers offer a great potential nanoplatform for the
controlled delivery of therapeutics to the placenta. While their toxicity profile has
not been studied in nearly as much detail as liposomes (at this time less
translational potential), it offers an opportunity to control the release in a more
predictable way, potential way to target fetal circulation and thus treat diseases of
the fetus, and it is yet biodegradable and can also be excreted. In this Chapter
we discuss the design, synthesis and modification of control polyester dendrimer
conjugates and most of the steps towards the preparation of the targeting
dendrimers. We also report some preliminary data on the pharmacokinetics of
the non-targeting PEGylated polyester dendrimer. Their half-life were determined
to be 4.1h, which compares with PAMAM with no PEG or low PEG density, as
expected, as the density of PEG in this case is limited. These dendrimers are
also almost completely eliminated after 24 hrs, which may be beneficial in terms
of eliminating long-term toxicity issues.
This work is in progress and we are in the process of synthesizing the
targeting dendrimer and assessing their pharmacokinetics. Subsequently, similar
methods of in vitro uptake study and in vivo biodistribution will be executed
based on what was reported in Chapter 2.

We expect to finish these

experiments shortly, as the timed pregnant mice reach the GD 18 within the
coming weeks.
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CHAPTER 4
CONCLUSIONS AND FUTURE WORK
Pregnancy-related complications are the major threat for the expecting
mother and/or fetus because of the wide range of consequences that are
associated with them. Preeclampsia, for instance, can lead to severe
consequences for both the mother and fetus especially if not managed. It can
lead to maternal and fetal morbidity and mortality (Jim and Karumanchi, 2017;
Roberts and Gammill, 2005). IUGR is also another common disease of
pregnancy that affects the growing fetus and is associated with preterm birth,
which is also a major problem associated with pregnancy, contributing to
approximately one million deaths annually (Goldenberg et al., 2008; Simmons et
al., 2010). Unfortunately, there are no prescribed treatments to any of such
complications; however, in some cases, a few medications are given to control
the symptoms associated with those diseases. For example while preeclampsia
does not have a treatment (besides delivering the babby), the high blood
pressure associated with it is controlled by hypertension medications. Preterm
birth may also be controlled using agents that can stop the uterine muscle
contractions leading to delayed labor; however, preventing premature birth by
simply stopping the uterine muscle contractions may not necessarily provide
neonatal positive outcomes. Therefore, serious efforts with regards to developing
treatments in obstetrics and gynecology are needed. Along with that, the
development of formulations that can safely and efficaciously deliver the cargo is
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critical so that the health of the mother and fetus is minimally affected by the
treatment (Keelan et al., 2015b).
Our efforts to establish a nanoplatform that can be utilized to deliver
therapeutic molecules in a targeted manner to the placenta, which is a major
organ whose dysfunctions lead to many of the mentioned complications, are
expected to support the development of such safe and effective formulations for
treating diseases of the pregnancy. More specifically, we designed targeting
nanocarriers that can bind megalin receptors expressed on the maternal side of
the placental-fetal interface, the SynT later. We explored our strategies using
existing well-established in vitro and in vivo models where megalin is also
expressed.
In this work, we established a 2D in vitro placental model consisting of
polarized monolayers of BeWo cells by culturing them and allowing them to grow
as a function of time to confluent monolayers that form tight junctions. Because
the SynT layer expresses certain receptors on the maternal side (apical side), the
polarization of the BeWo monolayers was essential in order to mimic such
conditions. We executed that by first seeding BeWo cells to porous membranes
and culturing them for 9 days. Throughout the cell growth, we assessed the
TEER values everyday. TEER values plateaued around 5-6 days, which is a
surrogate for the monolayer polarization. We also confirmed the monolayer
formation on day 6 by constructing cross-sections that show monolayers, and
polarization by staining the tight junctions to confirm the barrier properties of the
monolayers. Those results compared well / better then existing literature.
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Future work regarding this model is to establish a more complex 3D model
that can include more parameters and therefore be more representative of the
placental barrier. The 3D model can be developed with BeWo cells on one side
of the porous membrane, and fetal endothelial cells on the other side,
representing maternal to fetal circulation. Moreover, a microfluidic system would
enhance the flow properties on the apical side representing the maternal blood.
Such model would make it more relevant not only to evaluate placental uptake of
targeting nanocarriers but also transplacental crossing of agents from the
maternal to the fetal circulations. It may also improve phenotype of the in vitro
model.
On the other side, we successfully designed liposomes that can target the
megalin receptors expressed on the apical side of the in vitro model of the SynT
and enhance the uptake. DSPE-PEG-NH2 was linked with the GM without
modification of its amine groups. Using different molar ratios of this targeting lipid
(5% or 10%), we were able to prepare different liposomal formulations and
encapsulate FITC. We used 5% molar ratio of DSPE-PEG without the GM as a
control. All the three systems showed consistency in terms of hydrodynamic size,
surface charge, and encapsulation and release profiles, which were carefully
assessed and were critical to the ability to measure the targeting potential of the
nanocarriers. Our results showed enhanced uptake for both targeting systems
compared to the control. We also concluded that higher density of DSPE-PEGGM further enhances the uptake compared to the (5%) confirming that the
uptake is megalin-mediated endocytosis. Furthermore, we tested the 5%
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targeting liposomes with the non-targeting liposomes under different conditions.
First, we tested the liposomal uptake in the presence and absence of 2 mM free
GM as a method to saturate megalin receptors. Our results showed significant
uptake reduction of the targeting liposomes in the presence of the free GM,
further confirming liposomes are taken up via receptor-mediated endocytosis.
Second, we tested the uptake of the same formulations on a different cell line
(HepG2) that is known not to express megalin receptors. Results showed no
significant difference between the two systems further confirming our hypothesis
that modification nanocarriers with GM will results in enhanced uptake in
megalin-expressing cells.
After concluding the positive results from the in vitro study, we
successfully established an in vivo model using timed-pregnant female Balb/c
mice. Liposomal formulations were altered to contain a near infrared dye. Cy5.5
was then conjugated to DSPE-PEG-NH2 to replace FITC Encapsulation in order
to establish a more robust strategy to assess the targeting / tissue biodistribution
as the probe is not encapsulated but conjugated to the lipid, thus allowing us to
directly assess the uptake of the nanocarrier/lipis instead of free probe that may
be released in systemic circulation. We developed and implemented a new
animal protocol for sourcing

timed-pregnant mice.

Targeting studies were

performed on gestational day (GD) 18.5 as it represents the third trimester, as
the placental barrier of mice and humans is functionally analogous at that time
point of pregnancy (Georgiades et al., 2002). We performed biodistribution
analysis at 4h post treatment based on previous studies performed with similar
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PEGylated liposomes. Results showed enhanced targeting efficiency to the
placental tissue for the GM liposomes compared to both the non-targeting
liposomes and free drug model (Cy5.5) (P<00001). Kidneys also showed
enhanced uptake as was expected due to the presence of megalin receptors in
that tissue. Finally, fetal concentration showed no significant uptake between the
two liposomal systems and the free Cy5.5, which was a positive outcome as at
this point we sought to avoid reaching fetal circulation. However, more studies
are required to probe the kinetics of biodistribution of the nanocarriers. Also,
there are different scenarios here. One may be interested in preventing the
nanocarriers to reach the fetal circulation for safety reasons, but further
consideration as to the potential of nanocarriers reaching the fetal circulation to
treat specific fetal diseases should be considered as for example targeting neural
inflammation. This work shows the capability of GM-modified nanocarriers to
target megalin receptor expressing cells and deliver therapeutics to the placenta.
Further investigation of the fetal and maternal concentrations of payloads (not
only carrier) are needed, including small molecules and biologics to understand
their true potential. Other areas to explore here including varying the PEG length,
density (and targeting density), and the use of other targeting ligands that may
further enhance uptake in the SynT.
In conclusion, this work has established a viable nanoplatform for the
targeted delivery of therapeutics to the placenta for the treatment of placentalbased pregnancy complications.
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There are many other interesting future studies/ directions for this
formulation. From my perspective, one of the most attractive would be
encapsulating short interfering RNA (siRNA) for the treatment of preeclampsia.
siRNA is unstable in blood and easily degraded, thus, its encapsulation would
add several advantages including, stability, longer circulation, sustained release
and targeted delivery.
Preeclampsia is a common disease of pregnancy and a leading cause of
maternal deaths. In the recent years, it has been linked to an imbalance of
angiogenic factors leading to less angiogenesis in the placenta and consequently
preeclamptic symptoms including high blood pressure. More specifically, soluble
fms-like tyrosine kinase-1 (sFlt-1 or sVEGFR-1) has been reported to be
excessively expressed in placental tissue. Therefore, targeted delivery of siRNA
to the placental tissue in order to knock down the expression of the
corresponding genes would be a valuable direction to consider.
Extending this work to ex vivo studies of perfused human placenta and
more relevant animal models, including non-human primates would be also
helpful to test the approach in more relevant models. Some studies have used
such model to assess the transplacental crossing of nanocarriers. PAMAM
dendrimers, for instance showed a low rate of transfer from maternal to the fetal
side across the perfused human placenta where others have used similar ex vivo
model to show that the transplacental crossing of warfarin can be minimized
when encapsulated in cationic liposomes (Bajoria et al., 2013).
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Dendrimers nanocarriers (DNCs) were also used in the project in order to
evaluate the GM targeting using a different platform than liposomes. We believe
because of their size and stability, megalin-targeting dendrimers may be able to
not only hitchhike through the megalin-mediated endocytosis, but also transport
to the fetal circulation, and that would be a major breakthrough. Dendrimers are
significantly smaller than liposomes and provide for the ability to carry a higher
payload and implement triggered release mechanisms. While we are about to
execute the experiments with the targeting dendrimers, we did not have time to
report here the outcome of those experiments. We show, however, that we were
able to modify polyester dendrimers with two Cy5.5 molecules. Cy5.5 is a near
infrared dye that is important in tracking the distribution of the nanocarrier. We
also show that the CY-Dendrimer was successfully conjugated with 10 PEG1000
molecules, and we are currently working on the conjugation of PEG with the GM
targeting ligand. Here PK studies will help us decide optimum time to get the
preliminary biodistribution studies. Besides that, the protocols for the in vitro and
in vivo studies have already been established and we should be able to execute
the studies as soon as the chemistry is done. In the mean time, we will start by
measuring the biodistribution of the PEGylated dendrimers with Cy5.5.
PEGylation alone is expected to improve partitioning to the placenta compared to
free probe as we observed with the liposomes due to improved systemic
circulation and extensive irrigation and surface area of the SynT.
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APPENDIX

Scheme S2.1: Schematic of the chemical synthesis of Cy5.5-modified DSPE2KPEG lipid (DSPE-PEG2K-CY).
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Figure S2.1: MALDI-ToF showing the peak shifts for DSPE-PEG2K-CY
compared to DSPE-PEG2K (ca. 2790 Da, Figure 2). Cy5.5 with 619 Da.
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Figure S2.2. (a) Increase in transepithelial electrical resistance (TEER) of
BeWo monolayers as a function of time. The figure shows the increasing
TEER values of this study compared to other previously reported work(Hong
et al., 2009; Poulsen et al., 2009). Note a shift in TEER at day 7. Based on
cross section micrographs this corresponds to the formation of multilayers (b).
Our work is all at day 6 when BeWo is in monolayer form and polarized (b) as
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Table S2.1. Hydrodynamic Diameter (HD) and Zeta Potential (ζ) of the In
Vivo Liposomal Formulations. SD = standard deviation, n = 4.
Liposomes

HD

10PEG2K-0GM-CY

103 ± 3

- 5.4 ± 2.3

10PEG2K-10GM-CY

114 ± 4

- 3.4 ± 1.3

SD (nm)

ζ (mV)

80

Intensity (%)

100

7958

8721

G4-NH2
G4-FITC
G4-FITC-GB

18266

50

0

0

10000

20000

Mass (m/z)

30000
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Figure S3.1 MALDI ToF and 1H NMR showing successful modification of
polyester dendrimer with FITC and GM.
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Figure S3.2 MALDI-ToF peak showing the successful partial conversion of –OH
to –NH2 (15), 7498 Da
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Figure S3.3 MADLI-ToF results showing the peak of G4OH-CY at 8600 Da
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Figure S3.4 MADLI-ToF results showing the peak of G4OH-CY conjugation of
mPEG1K at 17000 Da
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Figure S3.5 Detailed 1H NMR spectra of (a) Cy5.5, (b) dendrimer, (c) G4OHCY, and (d) G4OH-CY-mPEG1000.

1

H NMR Explanation

A fourth generation polyester dendrimer was first modified with a protected
amino acid (linker) in order to add terminal amino groups to the dendrimer.
This amino groups would have a higher nucleophilicity and would increase
the efficiency of the reaction between the dendrimer and the dye (Cy5.5). The
reaction with boc-protected amino hexanoic acid, and subsequently
deprotection, led to the appearance of new peaks related to the -CH2 groups
from the amino acid (1.31, 1.51, 1.57, 2.28, 2.74 ppm). Those peaks were
used to assign the number of conjugated linkers, what as calculated as 17.
After this first modification, the macromolecule was reacted with Cy5.5
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forming an amide bond between the linker and the dye. The conjugation of
the dye was checked by the appearance of peaks in the 7.5-8.5 ppm range
(related to the rings and double bonds of the structure) and the number of
conjugates was determined through the integration of the peak at 6.35 ppm.
This peak was selected due to the fact that it is very isolated from other peaks
and no overlap was observed. The integration of it showed the conjugation of
1.8 molecules of dye per dendrimer.
After the obtainment of the labeled dendrimer, it was reacted with
mPEGCOOH (1,000 Da) and the purified macromolecule was analyzed
through 1H NMR. The conjugation of mPEG resulted in the appearance of a
very intense peak at 3.51 ppm, which is correspondent to the -CH2 units of
the polymeric chain. To quantify the number of polymer chains connected, it
was used the integration of the terminal methyl group (-CH3) of mPEG at 3.24
ppm. It was determined that was conjugated 10.2 PEG chains per dendrimer.
Additionally, in the spectrum of this final structure it is possible to observe the
peaks of Cy5.5 showcasing that the dye was not affected by the reaction
between dendrimer and mPEG.
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Figure S3.6 MALDI-ToF peak (200089 Da) showing the successful conjugation
of HOOC-PEG-NH2-BOC to the G4-CY.
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ABSTRACT
GENTAMICIN-MODIFIED NANOCARRIERS FOR PLACENTAL TARGETED
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by
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Diseases of pregnancy are the leading cause of maternal and neonatal
morbidity and mortality affecting more than 20% of all pregnancies annually.
Those diseases include preeclampsia, preterm labor, and intrauterine growth
restriction, many of which are caused by placental dysfunctions. Placenta is a
specialized organ that creates a maternal-fetal interface. It provides many
functions that contribute to the fetal development. Unfortunately, there is
currently no treatment for such diseases. Our work focuses on the development
of a novel nanoplatform that can be used to target the placenta so as to deliver
therapeutics, which can be encapsulated or conjugated to the nanoformulations.
In this work, we have established and characterized an in vitro placental
model based on BeWo cell monolayers that mimic the placental barrier, the
syncytiotrophoblast. Next, we synthesized lipid conjugates with gentamicin, as a
targeting moiety that is a substrate to megalin receptors, which are expressed on
the maternal (apical) side of the syncytiotrophoblast. Using those targeting lipids,
we successfully prepared and characterized targeting liposomes nanocarriers
and showed that they are more significantly taken up by the BeWo polarized
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monolayers compared to liposomes lacking the targeting lipid. Furthermore, we
tested our liposomal formulations under different conditions: 1) saturated megalin
receptors 2) a different cell line (HepG2) that does not express megalin. Results
reinforced the ability of the liposomes to target the in vitro syncytiotrophoblast
model and that the internalization mechanism is megalin-mediated endocytosis.
Subsequently, we established an in vivo model of the syncytiotrophoblast using
timed-pregnant Balb/c mice. On gestational day 18.5, we administered the
liposomal formulations and assessed the biodistribution in placentas, kidneys,
and fetuses. Placental analysis showed significant accumulation of the targeting
liposomes compared to the control non-targeting liposomes and the free Cy5.5
(drug model). Moreover, kidneys showed significant accumulation, which was
expected because those organs also express megalin receptors. Fetal tissues
showed no significant difference between the three groups suggesting that the
fetus should experience no toxicity due to limited exposure to the nanocarriers.
This conclusion confirms our hypothesis and satisfies our goal of successfully
establishing a nanoplatform for the targeted delivery of therapeutics to the
placenta.
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